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1. Introduction 
1.1 Pathophysiology of hemorrhagic shock  and sepsis  
 
1.1.1 Hemorrhagic shock and sepsis 
Hemorrhagic shock is commonly present in patients with multiple injuries in the early 
phase after trauma and represents one of the major pathophysiological events leading to a 
severe deterioration of the immune response. Hemorrhage is a condition with excessive 
external or internal blood loss [1, 2] and shock occurs when there is hypoperfusion of 
vital organs e.g. due to malfunction of the myocardium (cardiogenic shock), 
overwhelming infection leading to redistribution of circulating volume into the 
extravascular space (septic shock) or hypovolemia due to severe dehydration or 
hemorrhage (hypovolemic shock). Signs and symptoms of hemorrhagic shock vary 
depending on the volume and rate of blood loss [3]. Hemorrhagic shock leads to tissue 
hypoxia, acidosis, and the release of various mediators culminating the conditions to a 
systemic inflammatory response syndrome, SIRS [2, 4, 5]. SIRS can be due to infectious 
and non-infectious reasons. Along with hemorrhagic or hypovolemic shock, non-
infectious conditions include trauma, burns and acute pancreatitis [6, 7]. SIRS with a 
documented systemic infection is termed as sepsis. Therefore, sepsis is defined as 
systemic inflammatory response syndrome (SIRS) along with an overt infection [8-10] 
which can be caused by invading bacterial, viral, fungal or parasitic microorganism itself 
or various products or features of the organism such as endotoxin (LPS), peptidoglycan 
(PGN) or lipoteichoic acid (LTA) or specific bacterial toxins [10]. This systemic 
inflammatory response involves immune cell dysregulation and a complex network of 
cytokines. A massive deterioration of the immune response during hemorrhage and 
sepsis occurs that may result in multi-organ failure (MOF) and even death when gets 
uncontrolled [7, 11].  
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Figure 1. Hypothesis of the cascade of events after hemorrhagic shock that leads to the development of 
depressed immune responses and increased susceptibility to sepsis. GM-CSF generates new immune cells 
and activates circulating monocytes and resident macrophages and dendritic cells, maintaining 
immunocompetence following adverse circulatory conditions. The idea of the figure is from Angele MK et 
al [12]. 
 
1.2 Immune response and overview of cytokines 
A normal response to an infection involves a series of complex immunologic reactions 
including cytokine activation of cells against infection with pathogens by production of 
cytokines such as TNF-α, interferons, interleukins and chemokines. The systemic 
response to infection that leads to sepsis and septic shock is mediated by a complex 
cytokine network. Cecal ligation and puncture (CLP) in mice causes symptoms similar to 
those found in septic patients and serves as a model for peritonitis and polymicrobial 
sepsis. The model has been a mainstay of basic science sepsis research [13, 14]. The 
animal models for hemorrhagic shock and sepsis undoubtedly have helped in gaining a 
better understanding of the immune response of the patients. In alignment with this idea 
similar changes in the immune system have been described in trauma and septic patients, 
as well as mice and rats after hemorrhagic shock and sepsis. Hemorrhagic shock leads to 
decreased LPS-dependent proinflammatory cytokine response of various macrophages 
which is associated with an increased susceptibility to bacterial infections. A dampened 
production of TNF-α, IL-6, IL-8 and IL-12 after stimulation with endotoxin has also 
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been shown from patients with multiple injuries [15, 16]. Hemorrhagic shock in mice and 
rats has been found to reduce LPS-induced TNF-α and IL-1β by splenic macrophages 
[17-19]. A reduction in TNF-α producing capacity of whole blood or peripheral white 
blood cells after hemorrhagic shock has been shown by many other groups [20]. 
Impaired induction of IL-10 expression has also been shown in the lung following 
hemorrhagic shock [21]. In contrast to splenic, peritoneal, and alveolar macrophages, 
Kupffer cells have been shown to have an enhanced capacity to produce pro-
inflammatory cytokines, i.e. IL-1, IL-6, and TNF-α during the first 24 h after hemorrhage 
[22]. Similarly, an increase in cell associated TNF-α has been demonstrated on Kupffer 
cells, but not on splenic macrophages, at 2 h after hemorrhagic shock and resuscitation 
[23]. It should be noted that Kupffer cells and splenic and peritoneal macrophages are 
located in different microenvironments. Thus, the data suggest that trauma and 
hemorrhagic shock produce different effects on different tissue beds. Alternatively, 
splenic macrophages are in close contact with T cells, and mediators released by these 
cells after hemorrhage might depress the responsiveness of these macrophages as 
compared to Kupffer cells. Despite the differential cytokine release capacities of 
macrophages from different microenvironments, the antigen presentation capacity was 
depressed by macrophages in all tissue beds. Overall the suppressed cytokine production 
in hemorrhagic shock can be assumed as a phenomenon for immunosuppression. 
Immune reactions during sepsis can be conceptualized as occurrence of an early pro-
inflammatory and late compensatory anti-inflammatory response. The stringent 
expression of both responses seems to be decisive to determine the outcome of disease. 
An early pro-inflammatory response is characterized by the release of pro-inflammatory 
mediators, including TNF-α, IL-1β, IL-6 and chemokines (referred to as the systemic 
inflammatory response syndrome [SIRS]). Proinflammatory cytokine expression is 
counter-regulated by the release of anti-inflammatory cytokines such as IL-10 and IL-4. 
The latter response is generally termed as compensatory anti-inflammatory response 
syndrome (CARS) (Figure 2). The latter phase is believed to mediate the profound state 
of immunosuppression which occurs in association with substantial impairment in 
immune functions (sepsis-induced leukocyte “deactivation” or “immunoparalysis” [24]. 
 
 
 
 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Expression of cytokines during sepsis. 
As depicted in the graph, sepsis is characterized initially by an exuberant production of pro-inflammatory 
cytokines, leukocyte activation and tissue injury which is then followed by a release of anti-inflammatory 
cytokines, leukocyte deactivation and immunosuppression. The figure is adapted with required 
modification from van der Poll et al. [25]. 
 
The double edged role of the inflammatory response after hemorrhagic shock becomes 
most obvious for TNF-α. A primary role for TNF-α in sepsis or endotoxic shock is 
suggested by several research groups. On one hand, peak in the serum TNF-α levels in 
patients with sepsis, correlates with the mortality [26] and its neutralization helps 
ameliorating the survival [27]. Antibodies against TNF-α are shown to antagonize the 
lethal effects of endotoxin [28, 29] and also improve survival after lethal hemorrhagic 
shock [27, 30]. In aggregate, TNF-α neutralization yields a small but statistically 
significant benefit [31] for the early inflammatory phase showing high TNF-α. On the 
other hand, TNF-α is essential for an adequate immune response to infectious invaders. 
In contrast to the effect of high circulating TNF-α causing endothelial cell damage 
resulting in systemic oedema, hypotension and multiple organ failure [32], local TNF-α 
secretion is absolutely necessary to cope with infectious disease. Local effects of TNF-α 
include increased migration of macrophages, lymphocytes and polymorphonuclear 
leukocytes to the site of infection as well as enhanced release of antibodies, complement 
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and acute phase proteins [33]. Finally, TNF-α elimination by disruption of the gene of 
the TNF p55 receptor in ‘knock out mice’ prevented the establishment of an adequate 
immune response against Mycobacterium tuberculosis or Listeria monocytogenes [34, 
35].  
IL-10 has been most thoroughly studied out of all anti-inflammatory cytokines [36]. 
Synthesis of IL-10 is stimulated by pro-inflammatory cytokines like TNF-α, IL-1β, IL-6 
and  IL-12. IL-12 and its counterpart IL-10 play a critical role during sepsis since 
modulation of these cytokines influences sepsis-induced mortality. Recombinant IL-10 
treatment, prior to CLP strengthens the survival [37] administration of IL-12  [38] 
increases sepsis-induced mortality. However, the time of intervention appears to be 
decisive for disease development. Absence of IL-10 during the initial inflammatory 
phase of sepsis is detrimental [39] whereas neutralization of IL-10 at later time points of 
anti-inflammatory phase is found to be beneficial [40-42].  
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1.3 Antigen presenting cells  
The antigen presentation is considered to be a key function in hemorrhage and sepsis-
induced inflammatory response. Monocytes’, macrophages’ and dendritic cells’ function 
as antigen presenting cells are well studied in regard to outcome of the disease [6, 43, 
44]. 
 
1.3.1  Monocytes and macrophages 
An intact and healthy monocyte and macrophage function is mandatory for the 
successful primary fight against infection. A depressed production of various cytokines 
has been observed in both monocytes of severely injured patients and macrophages of 
various origins in mice sustained to severe hemorrhage. Whole blood cultures and 
isolated mononuclear cells from patients with multiple injuries demonstrate a dampened 
production of TNF-α, IL-6, IL-8 and IL-12 after stimulation with endotoxin [15, 16]. 
Similarly, splenic macrophages from mice isolated after severe hemorrhage demonstrate 
a decreased synthesis of TNF-α, IFN-γ, IL-2 and IL-6 [45, 46]. Severe injury and sepsis 
are frequently associated with a suppression of antigen presentation capacity and lack of 
ready response of monocytes, analyzed by the HLA-DR expression as well as a 
diminished capacity to produce cytokines such as TNF-α, IL-6 and IL-8 [45]. Low 
expression of HLA-DR [47] has been shown and correlated with disease state and 
mortality in septic patients [48-50]. 
 
1.3.1.1 Signaling mechanism of monocytes and macrophages 
Activation of macrophages by LPS is commonly considered as a model for the primary 
response of the innate immune system to invading bacteria. Therefore, the LPS-
dependent activation and intracellular signaling cascade has been analyzed extensively. 
Upon activation with LPS, multiple signaling pathways are activated in monocytes or 
macrophages (Figure 3A and B), such as the nuclear transcription factor NFκB and the 
mitogen-activated protein kinase (MAPK) pathway [51]. NFκB is under control of its 
inhibitor IκB, which is phosphorylated upon cellular stimulation with e.g. endotoxin and 
then liberates the active transcription factor [52-54]. MAPKs are signaling molecules, 
considered to be important in the regulation of various effector functions of macrophage 
and thereby regulate the inflammatory process [55]. These enzymes consist of proteins 
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that belong to three different families: extra cellular signal-regulating kinases (ERK), 
P38MAPK, and c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK). 
MAPK activity is involved in the early stress response caused by hemorrhage as shown 
for example in the lung tissue immediately after hemorrhage [56]. However, similar to 
the cytokine response, which is also increased early after hemorrhage followed by a 
downregulation, the activation of these signaling molecules parallels this pattern [57]. At 
least in severely injured patients the impaired cytokine response is accompanied by a 
reduced endotoxin-dependent activation of the nuclear transcription factor NFκB in 
human monocytes [58, 59]. Correspondingly, after hemorrhagic shock and laparotomy in 
female mice a lower endotoxin-induced phosphorylation of P38MAPK was observed in 
spleen cells in comparison to sham-operated mice [60]. 
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Figure 3. Signaling pathways in macrophages upon LPS activation.  
A) LPS stimulation of monocytes activates different signaling pathways and consequently produces TNF. 
B) LPS binds to LPS-binding protein (LBP) in plasma and is delivered to the cell surface receptor CD14. 
Next, LPS is transferred to the transmembrane signaling receptor toll-like receptor 4 (TLR4). LPS 
stimulation of human monocytes activates several intracellular signaling pathways that include three 
mitogen-activated protein kinase (MAPK) pathways: extracellular signal-regulated kinases (ERK) 1 and 2, 
P38 and c-Jun N-terminal kinase (JNK). In addition, LPS activates the IkappaB kinase (IKK)-NF-kappaB 
pathway via MyD88 and IRAK which in turn phosphorylated the IκBs. Subsequent degradation by 
ubiquitination of IκBs permits nuclear translocation of active NFκB. These MAPK and NF-κB signaling 
pathways in turn activate a variety of transcription factors like NF-kappaB (p50/p65) and AP-1 (c-Fos/c-
Jun) which coordinate the induction of many genes encoding inflammatory mediators. The figure is 
adapted with required modifications from Beutler et al [61]. 
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1.3.2  Dendritic cells 
 
1.3.2.1 Dendritic cell development 
Dendritic cells (DC), first described by Steinman et al in 1972, are the most potent 
antigen-presenting cells and are sentinels of the immune system. Dendritic cells are 
derived from the CD34+ bone marrow progenitors that separate into lymphoid and 
myeloid lineages to develop lymphoid and myeloid DC respectively [62]. These are the 
two distinct lineages of dendritic cell development which have been identified in mice. 
Lymphoid and myeloid DC differ in phenotype, localization and function. Both subsets 
express high levels of CD11c, MHC class II and the co-stimulatory molecules CD86 and 
CD40. CD8α is the most reliable marker known till date to distinguish these subsets. 
CD8α is expressed as a homodimer on the lymphoid DC but is absent from the myeloid 
DC subset. The common myeloid marker CD11b is expressed on myeloid CD8α- DC but 
not on CD8α+ DC. Furthermore, the presence of GM-CSF expands the CD34+ bone 
marrow progenitors to develop preferentially into myeloid DC [62, 63]. 
 
1.3.2.2 Antigen capture, migration and maturation of dendritic cells  
Newly generated DC migrate from the bone marrow to lymphoid and nonlymphoid 
tissues and become resident cells. They are located in most tissues of the body where 
they readily encounter invading microorganisms. Immature DC are very efficient in 
antigen capture and can use several pathways, such as macropinocytosis, receptor-
mediated endocytosis and phagocytosis. DC in peripheral tissues process the captured 
microbial or viral antigens and migrate to the draining lymphoid organ where they 
interact with antigen-specific T cells [64]. During migration, these DC undergo major 
morphological, phenotypical and functional changes termed as maturation. Upon 
maturation, DC strongly upregulate MHC and co-stimulatory molecules like CD86, 
CD80, and CD40, all of which are mandatory for effective antigen presentation and T 
cell stimulation [65]. Due to high levels of MHC class II and co-stimulatory molecules, 
mature DC are very potent T cell activators and are superior in comparison to other 
antigen-presenting cells like macrophages or B cell, [66]. In contrast, DC that lack high 
levels of co-stimulatory molecules and/or do not secrete pro-inflammatory cytokines are 
involved in tolerance induction. In this case tolerance is mediated through activation of 
regulatory T (Treg) cells or through induction of T cell apoptosis [67]. Thus, depending 
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on the pattern of co-stimulatory molecules and secreted cytokines, DC determine the fate 
of the immune response [68]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Features which change during DC maturation. 
Immature DC take up and process antigen and then migrate to secondary lymphoid organs. During 
migration DC undergo a process of maturation. Examples of pathogenic molecules that induce maturation 
are lipopolysaccharide (LPS), bacterial DNA, CpG. TNF-α and GM-CSF are examples of cytokines, and 
CD40L is an example of a T-cell ligand that binds CD40 on DC and induce maturation. The figure is 
adapted with required modifications from Banchereau et al [64]. 
 
1.3.2.3 Dendritic cell-induced Th cell polarization 
Dendritic cells not only induce T cells to secrete cytokines but are also themselves an 
important source of cytokines such as TNF-α, IL-1α/β, IL-6, IL-8, IL-10, IL-12, TGF-β 
and IFN-α/β [69]. During maturation, DC polarize T helper (Th) cells towards Th1 or 
Th2-type cells depending on the duration of the DC-T cell interaction, as well as the type 
of the secreted cytokines by the DC at the time of interaction (Figure 5) [70, 71]. DC 
that induce a Th1 or Th2 response are termed DC1 and DC2 respectively [72]. The DC1-
derived cytokine IL-12 favors the differentiation of Th1 cells to secrete IFN-γ and is 
important for the development of immunity against bacterial infections [73, 74]. In 
contrast, DC2-derived IL-10 promotes the polarization of Th cells towards Th2 to secrete 
IL-4, IL-5 and IL-10 that mediates immunity against extracellular parasites [64, 73, 74]. 
Some other cytokines like IL-3 and TNF-α are produced by both Th1 and Th2 cells. 
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Figure 5. Dendritic cells induced Th cell polarization. 
Subsets of DC induce T cells to differentiate towards a particular clone. If stimulated by gram negative 
bacteria (LPS), the DC mature into a DC1 phenotype that induces naïve T cells to become Th1 cells. On the 
other hand, if exposed to antigens from certain helminthes, the DC mature into a DC2 phenotype that 
induce naïve T cells to a predominantly Th2 phenotype.  
 
1.3.2.4 Dendritic cells during polymicrobial sepsis 
DC are the central players in the activation of both innate and adaptive immunity and a 
decision maker in T cell activation [62]. A potentially deviated DC biology, function and 
behavior could be responsible for immunosuppression observed during shock and sepsis.  
 
1.3.2.5 Dendritic cell loss during sepsis 
Indeed, apoptosis of DC in the spleen [75, 76], lymph nodes [77] and total bone marrow 
cells [78] during sepsis has been described, suggesting the involvement of DC during 
sepsis. The work from our own group provided evidence that selectively, the splenic 
CD4+CD8– and CD4–CD8+ DC subpopulations were lost during disease development and 
that remaining DC from septic mice were inhibited in their capacity for T cell activation. 
Furthermore, depletion  of the CD11c expressing cell populations results in a decreased 
survival rate after CLP in mice indicating that normal numbers of CD11c+ DC are 
required for a successful outcome from severe sepsis [79].  
 
1.3.2.6 Dendritic cells characterization during sepsis 
In a murine CLP model, it has been shown that there is strong maturation of splenic DC 
[80]. This maturation process was not only restricted to the spleen as a central lymphoid 
compartment but also was observed in lymph nodes distant from the site of infection. 
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However, maturation of DC from lymph nodes of septic mice followed a slightly delayed 
kinetics in comparison with splenic DC. There was a selective loss of certain DC during 
sepsis. Splenic DC of septic mice are shown to have an aberration in the cytokine 
secretion pattern toward predominant IL-10 and a failure to secrete IL-12 [81]. 
Therefore, DC acquired a change in the phenotype which could favor the development of 
Th2 cells. Consequently, all these changes might be responsible for inhibiting the 
effective immune response against the bacterial components through Th1 cell 
polarization. 
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1.4 Scope and restoration response 
 
1.4.1 GM-CSF in general 
GM-CSF, one of the first cytokines to be characterized, identified and cloned, is a 23-
kDa, glycosylated, monomeric secreted protein. Murine and human GM-CSF share 
modest structural homology at the level of nucleotide (70%) and protein (56%) sequence 
[82] and do not exhibit cross-species receptor binding or biological activity. GM-CSF is 
produced by a variety of cell types including monocytes, endothelial cells, fibroblasts, 
mitogen-stimulated B-cells, T-cells and LPS-stimulated macrophages, [83, 84]. Amongst 
these, monocytes, macrophages and activated T cells are the primary producers of GM-
CSF [84]. These cells sense invading pathogens and produce GM-CSF as part of their 
response. Also, they stimulate other cells, fibroblasts and endothelial cells, to produce 
GM-CSF secondarily. GM-CSF then works in coordination with other cytokines, IL-5 
and IL-3, to maximize the granulocytic inflammatory response [85, 86]. 
 
1.4.2 GM-CSF as an immunomodulator 
GM-CSF is an important hematopoietic growth factor and immune stimulator. It is 
known to ameliorate the activation potential of monocytes which play an important role 
in the immune surveillance against many pathological conditions showing deactivation 
of monocyte functions. GM-CSF has a well recognized effect on granulocyte and 
macrophage maturation from hematopoietic precursors both in vitro and in vivo. In 
addition, GM-CSF also exerts effects on mature monocytes or macrophages and is 
known to potentiate the release of various cytokines such as TNF-α, IL-1β and IL-12 
after LPS stimulation without inducing these mediators by its own [87, 88]. GM-CSF has 
also been shown to amplify the response of the mature immune system to antigen. 
Because of its myeloproliferative and immunostimulatory properties, GM-CSF is widely 
used therapeutically in a number of clinical therapies such as myelosuppressive 
chemotherapy [89], bone marrow transplantation [90], neonatal sepsis [91], lung injury 
[92], and wound healing [93]. The augmenting effects of GM-CSF have also been 
recognized in hemorrhagic shock [94] and sepsis [95]. 
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1.4.3 Effect of GM-CSF on mature monocytes and macrophages 
Beside its extensively studied role in differentiation and proliferation of monocytes and 
granulocytes, GM-CSF alters functions of mature monocytes and macrophages. It binds 
to high-affinity specific receptor found on most monocytes and has been proposed to 
enhance their activation potential [96]. Various ex vivo studies demonstrate that GM-CSF 
upregulates HLA-DR expression on the surface of monocytes and macrophages [97]. 
GM-CSF stimulates the differentiation of monocytes to macrophages and primes them to 
enhance the synthesis of TNF-α, IL-8 and IL-6 [46]. GM-CSF preferentially and 
selectively reactivated effectors of the innate immune response (monocytes and 
macrophages), without affecting the silenced adaptive immune response of T cells that 
are causally involved in graft rejection [98, 99]. Therefore, GM-CSF ameliorated the 
resistance to bacterial infection without compromising the graft. 
 
 
GM-CSF in monocytes and mature macrophages: 
 
¾ Stimulation for granulocytes and monocytes 
¾ Activation of mature macrophages in terms of: 
 
• Surface markers MHC Class II, (KK) 
 
• Production of various cytokines (TNF, IL-8, IL-6..) 
after secondary stimuli such as LPS – “priming” 
 
• Elimination of bacteria (KK) 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.4 Signal cascade activated by GM-CSF 
The effects of GM-CSF are mediated through a heteromeric receptor expressed on 
monocytes, macrophages and granulocytes [100]. The GM-CSF receptor is composed of 
GM-CSF specific α and a signal transducing β chain that is common to receptors for 
GM-CSF, IL-3 and IL-5 [101, 102]. Although the GM-CSF receptor itself is devoid of 
tyrosine kinase activity the phosphorylation of a large number of intracellular signaling 
molecules occurs upon GM-CSF binding to the receptor [103]. GM-CSF binds with low 
affinity to the α-chain, which then associates with the β-chain, thus increasing a chain 
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binding affinity, and initiates JAK2 autophosphorylation [104] and post receptor 
signaling. Signal transmission occurs through multiple pathways, each requiring distinct 
regions of the α [105] and β [106, 107] receptor chains (Figure 6). GM-CSF mediated 
intracellular signaling molecules include members of the signal transducer and activator 
of transcription (STAT) family, the Ras/Raf-1 system and several mitogen-activated 
protein kinases (MAPK) [101, 102, 108-110]. GM-CSF was found to activate STAT 3 
and 5 in human neutrophils via phosphorylation mediated by a receptor-associated Janus 
family tyrosine kinase 2 (JAK2) [111]. GM-CSF also activates Ras [112] and Raf-1 
[113], P38 MAPK [114, 115] and the extracellular signal-related kinase 1 and 2 
(ERK1/2) [116]. In the activation of ERK1/2 the cytoplasmic part of the β receptor, the 
adapter protein Shc, Ras and Raf-1 and consecutive activation of the ERK kinase 
MEK1/2 appears to be involved. ERK1 and ERK2 are not the only MAPK that are 
activated by GM-CSF. Phosphorylation of P38, a kinase involved in cellular responses to 
stress, by GM-CSF stimulation has been reported to occur in human neutrophils [117]. 
Activation of the third group of MAPK, the JNK/SAPK kinases, by GM-CSF in different 
types of cells was also observed [118-121]. The mechanism through which this pathway 
is activated is not completely understood but JAK2 are likely to take part [118, 119]. 
GM-CSF also activates PI3K in the cells, an event dependent on tyrosine 
phosphorylation [113, 122-126]. Kinases that are downstream of PI3K are also activated 
by GM-CSF. PKB is shown to be rapidly activated by GM-CSF in human granulocytes, 
a process dependent on PI3K [123, 127]. However, there is no direct evidence for GM-
CSF-mediated direct activation of NFκB in monocytes or macrophages. 
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Figure 6. GM-CSF signaling pathway. 
GM-CSF binds to high affinity GM-CSF receptor and initiates JAK2 autophosphorylation bound to the β 
subunit. Phosphorylation of JAK2 results to multiple signaling pathway including STAT1,3,5, PI3K and 
various MAPK culminating into different transcription factors.  
 
1.4.5 GM-CSF in shock, trauma and sepsis 
1.4.5.1 GM-CSF in hemorrhagic shock 
The immune functions after hemorrhagic shock in experimental settings or after severe 
injury in patients, however, is not irreversible, but can be counteracted by 
immunostimulating compounds. GM-CSF, which stimulates proliferation and 
differentiation of myeloid bone marrow progenitor cells, can also enhance effector 
functions of mature monocytes and macrophages. On the basis of this function, GM-CSF 
has been shown to counteract the depressed TNF-α-producing capacity after severe 
trauma as well as the reduced expression of antigen-presenting Human Leukocyte 
Antigen (HLA)-DR on the surface of human monocytes after septic shock [96, 97]. GM-
CSF has been reported to restore the reduced TNF-α production by splenic and 
peritoneal macrophages after hemorrhagic shock in rats [94]. On the other hand, GM-
CSF contributes to relevant cytokine production of TNF-α, IL-1 and IL-6 in LPS-
mediated septic shock [128, 129]. 
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1.4.5.2 GM-CSF in sepsis  
During sepsis, early systemic hyper-inflammation induces systemic anti or hypo-
inflammation which can lead to “immunoparalysis”. Sepsis being a biphasic syndrome 
may require an immunomodulating therapeutic approach targeting the patient’s 
immunocompetence. A patient with sepsis in a stage of hyper-inflammation may need 
anti-inflammatory therapy and on the other hand a patient in “immunoparalysis” needs 
immunoreconstitution or immunostimulatory therapy [130]. It has been proposed that the 
later anti-inflammatory response causes monocytes to downregulate HLA-DR expression 
and become deactivated or dysfunctional indicating an enhanced susceptibility to 
infection [131, 132]. Also, a deficit in circulatory GM-CSF was observed in the patients 
with the systemic inflammatory response syndrome (SIRS) suggesting that these patients 
may have a decreased ability to activate their monocytes [133, 134]. GM-CSF may 
restore the activation potential of monocytes. Reversal of immunoparalysis has been 
reported by rhGM-CSF in patients with severe sepsis where GM-CSF administration 
upregulated HLA-DR expression on monocytes. Furthermore, with the elevated TNF-α 
response, this upregulation of a monocytic activation marker is paralleled by a functional 
recovery [95]. GM-CSF restored the response of monocytes by abrogating their 
spontaneous and activation-induced (LPS) apoptosis from septic patients [96]. GM-CSF 
is proposed to restore immunologic functions from septic patients [96] and can prevent 
immune paralysis in endotoxin-desensitized mice [135]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
GM-CSF in shock and sepsis: 
 
¾ Restores the activation potential of monocytes 
 
¾ Restores depressed ex vivo TNF-α synthesis and  HLA-DR 
expression after trauma, and during sepsis in vitro 
 
¾ Counteracts downregulation of TNF-α response during in 
vitro and in vivo endotoxin tolerance  
 
¾ Normalizes depressed TNF-α response of peritoneal 
macrophages after hemorrhage in mice and rats in vivo 
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1.4.6 GM-CSF in other clinical applications 
GM-CSF, being a myeloproliferative and immunostimulatory cytokine, has a wide range 
of applications in other pathological conditions. Because GM-CSF stimulates the 
production and speeds up the differentiation of myeloid progenitors, it has been widely 
used as an adjuvant to shorten the duration of neutropenia, time to complete therapy and 
mean total days of intravenous antibiotic use after myelosuppressive cancer 
chemotherapy [89, 136]. GM-CSF has been shown to promote myeloid engraftment in 
bone marrow transplantation [137, 138] or hematopoietic stem cell transplantation [139]. 
GM-CSF enhanced neutrophil proliferation and also upregulated bactericidal function of 
both neutrophils and monocytes and decreased mortality in critically ill septic 
neutropenic neonates  [91, 140, 141]. The positive response of GM-CSF treatment in 
neutropenic patients with infection raised the hope that stimulation by GM-CSF may aid 
critically ill non-neutropenic, sepsis patients to clear infection and ameliorate survival 
[142, 143]. Effect of GM-CSF could be of great clinical value to the patients with pre-
existing alveolar epithelial dysfunction and are markedly susceptible to acute lung injury. 
GM-CSF overexpression in the murine lung resulted in resistance to lethal acute lung 
injury because of hyperoxia [92]. GM-CSF has been reported in animal studies to 
promote healing of infected wounds [144] and has been shown to be effective, when 
given subcutaneously, in the management of chronic refractory wounds [93].  
 
 
GM-CSF in Clinics: 
 
¾ Established indication: 
• Bone marrow stimulation after myelosuppressive 
chemotherapy  
 
• promote myeloid engraftment in bone marrow 
transplantation 
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1.5 Aim of the Research 
 
Hemorrhagic shock and sepsis has been shown to induce immunosuppression by 
monocyte and macrophage deactivation, reducing antigen presentation, altering cytokine 
expression, modulating acquired immune response from a Th1 to Th2 type response and 
increased lymphocyte apoptosis. Progress in the realm of GM-CSF as an 
immunomodulator has enabled its potential to counteract the hemorrhage and sepsis-
induced immune dysfunctions partly or completely in both clinical and experimental 
approaches. Through the ongoing knowledge of GM-CSF in therapeutic applications in 
the field of trauma and sepsis, GM-CSF treated monocytes or macrophages may be 
confronted with bacterial components such as LPS. Although, the effect of GM-CSF on 
cytokine production by monocytes and macrophages after LPS-stimulation has been 
documented in the literature, the underlying intracellular mechanisms remain to be 
elucidated. The signaling events activated in monocytes or macrophages after stimulation 
with LPS or GM-CSF alone have been copiously described. However, the intracellular 
cascades activated in a combined stimulation with GM-CSF and LPS have not yet been 
investigated.  
The aim of the study was to analyze the effect of GM-CSF as an immunostimulatory 
substance after hemorrhage and cecal ligation and puncture (CLP), a model for severe 
polymicrobial sepsis. In particular, it was intended 1) to determine the effect of an in 
vitro treatment with GM-CSF of peritoneal macrophages for LPS-induced TNF-α 
production in a hemorrhagic shock model. 2) To determine the effect of an in vitro 
treatment with GM-CSF of splenic macrophages for LPS-induced TNF-α production and 
dendritic cells for CpG-treated IL-12 production during polymicrobial sepsis. 3) To 
explain the underlying mechanisms of GM-CSF activation of the TNF-α response in 
terms of IκBα (also NFκB) and MAPKinase (ERK1/2 and P38) signaling pathways. It is 
to be investigated first in normal human circulating monocytes, human monocytic cell 
line, THP-1 and then to be extended to the mouse model of hemorrhagic shock. It is well 
established especially for neutropenic septic patients suggesting a predominant effect of 
GM-CSF on the bone marrow. Therefore, the next aim of the study was to study the role 
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of GM-CSF as a growth regulator during polymicrobial sepsis especially for bone 
marrow derived dendritic cells. With the emphasis 4) to explain the GM-CSF effect on 
the bone marrow level during sepsis. To investigate whether sepsis additionally 
modulates bone marrow cells especially the progenitor cells of dendritic cells in terms of 
their differentiation, expression of co-stimulatory molecules, cytokine pattern and in vivo 
and in vitro antigen presentation capacity.  
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2. Materials and methods 
 
2.1 Chemicals, Reagents and Antibodies 
2.1.1 Chemicals  
All the chemicals and reagents used throughout this work were of analytical grade and 
purchased from different companies as stated in Table 1. 
 
Table 1: List of chemicals 
Name  Source (Supplier/Company) 
β-Mercaptoethanol Sigma, Deisenhofen Germany 
Acrylamide Fluka, Neu-Ulm, Germany 
Ammonium chloride Fluka 
Ammoniumpersulfate (APS) Promega, Mannheim, Germany 
Bicine Sigma 
Boric acid Sigma 
Bovine serum albumin (BSA) Sigma 
Bromophenol blue BioRad, Munich, Germany 
Calcium chloride Merck, Darmstadt, Germany 
Diethylether Merck 
di-Sodiumhydrogen phosphate Merck 
Dimethyl sulphoxide (DMSO) Sigma 
Dithiothreitol (DTT) Serva, Heidelberg, Germany 
EDTA Promega/Sigma 
Ethanol Backer, Griesheim, Germany 
Geneticin (G418) Invitrogen, Karlsruhe, Germany 
Glycerol Serva/Sigma 
Glycine Sigma/Merck 
HCl (32%) Merck 
HEPES Sigma/Serva 
Kanamycin Sigma 
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Leupeptin Sigma 
Magnesium chloride Sigma 
Methanol Backer 
Nonidet-P 40 Fluka 
Penicillin G Seromed, Munich, Germany 
PMA Sigma 
PMSF Roche, Mannheim, Germany 
Potassium chloride Merck 
Potassium hydrogen carbonate Fluka 
Sodium azide Merck 
Sodium chloride Merck/Fluka 
Sodium dihydrogen phosphate Merck 
Sodium dodecyl sulfate (SDS)/Lauryl sulfate Sigma 
Sodium hydroxide pellets Merck 
Streptomycin Seromed 
TBST Sigma 
TEMED Sigma 
Tris (hydroxymethyl)-aminomethane Sigma/Merck 
Tween-20 Sigma 
Urea Fluka 
 
2.1.2 Reagents 
Recombinant human GM-CSF derived from E. coli K12 (Molgramostin, Leucomax) was 
purchased from Novartis Pharma, Nürnberg, Germany. Murine recombinant GM-CSF 
and CD40 ligand (CD40L), IL-10 and IFN-γ were purchased from R&D systems, 
Wiesbaden, Germany. Synthetic phosphorothioated CpG 1668 oligonucleotides 
(Sequence: TCCATGACGTTCCTGATGCT) [145] were purchased from Qiagen, Köln, 
Germany. Concanavalin A (ConA), Dimethyl sulphoxide (DMSO), Ionomycin, 
Lipopolysaccharide (LPS, E. coli 026:B6), and Phorbol 12-Myristate 13-Acetate (PMA) 
were purchased from Sigma (Deisenhofen, Germany). Ova-peptide (OVA 323-339; 
peptide sequence: ISQAVHAAHAEINEAGR) was purchased from MoBiTec, Göttingen 
and PGN was purchased from InvivoGen, Hamburg, Germany. All reagents were free of 
detectable LPS contaminations as tested using Limulus amoebocyte assay. 
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2.1.3 Antibodies 
Antibodies were purchased from Acris (Hiddenhausen); Becton Dickinson (BD) 
Biosciences (Heidelberg), eBiosciences (Frankfurt); Caltag (Hamburg); R&D Systems 
(Wiesbaden-Nordenstadt), Immunotools (Friesoythe) Germany (Table 2). 
 
Table 2: Antibodies 
Antibody  Clone  Conjugation  
Amount 
( in 50 µl) Isotype Source  
CD16/CD32 2.4G2 No Conjugation 5 µl Rat IgG2b, κ BD PharMingen 
IL-10 JES5-16E3 No Conjugation --- Rat IgG2b, κ BD PharMingen  
IL-10 JES052A5 No Conjugation --- Rat IgG1 R&D Systems 
CD4 RM4-5 FITC  0.25 µg Rat IgG2a, κ BD PharMingen 
CD4 (L3T4)  YTS 191.1.2 FITC 2 µl Rat IgG2b ImmunoTools  
CD8α (Ly-2)  53-6.7 FITC  0.125 µg Rat IgG2a, κ BD PharMingen  
CD11b  M1/70  PerCP-Cy5.5 0.2 µg Rat IgG2b, κ BD PharMingen  
CD11c  HL3 APC  0.1 µg IgG1, λ BD PharMingen 
CD40  HM40-3 FITC 0.1 µg IgM, κ eBiosciences 
CD40  23-Mar FITC 0.25 µg Rat IgG2a, κ BD PharMingen  
CD45/CD14 2D1/MfP9 FITC/PE 20 µl Mouse IgG1 BD PharMingen 
CD86 (B7-2) GL1 PE 0.02 µg Rat IgG2a, κ BD PharMingen  
D011.10 TCR KJ1-26 APC 10 µg Rat IgG2a Caltag 
F4/80 Cl:A3-1(F4/80) APC 5 µl Rat IgG2b Acris 
Gr-1  RB6-8C5 FITC 0.5 µl Rat IgG2b ImmunoTools  
I-A/I-E 2G9 biotin  0.5 µg Rat IgG2a, κ BD PharMingen 
I-A/I-E 2G9 FITC 0.03 µg Rat IgG2a, κ BD PharMingen 
IFN-γ XMG1.2 PE 0.4 µg Rat IgG1 BD PharMingen 
IL-2 JES6-5H4 PE 0.2 µg Rat IgG2b BD PharMingen 
IL-4 11B11 PE 0.8 µg Rat IgG1 BD PharMingen 
IL-12  C15.6 PE 0.4 µg Rat IgG1 BD PharMingen 
TLR4/MD-2 MTS510 PE 0.4 µg Rat IgG2a, κ eBiosciences 
TNF-α MP6-XT22 PE 0.1 µg Rat IgG1 BD PharMingen 
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2.2 Culture media, Buffers and Solutions 
2.2.1 Culture media 
Very low endotoxin medium, VLE RPMI 1640 (Biochrom, Berlin, Germany) containing 
10% heat-inactivated fetal calf serum (FCS, Biochrom, Berlin, Germany) was used for 
all types of cultures. The FCS was heat inactivated for 30 min at 56°C. Medium was 
supplemented with 10 mM HEPES, 2 mM L-Glutamine, 0.06 mg/ml Penicillin, 0.02 
mg/ml Gentamicin and 0.05 mM β-Mercaptoethanol. 
 
2.2.2 Buffers and Solutions 
All the buffers were prepared in sterile conditions and filtered if necessary, through 0.22 
µm filter, to sterilize heat labile components. Millipore distilled three-fold deionised 
water was used for preparing the buffers.  
 
2.2.2.1 Cell isolation and culture  
Blendzyme Buffer (10 x, 50 ml) CaCl2 (133 mg); HEPES (1 M, 5 ml); KCl (186.4 
mg); MgCl2 (47.6 g); NaCl (4.383 g) 
RBC lysis buffer (0.15 M, 200 ml) KHCO3 (0.2 g); Na2EDTA.2H2O (7.44 g); NH4Cl 
(1.658 g) 
Cluster dissociation buffer 7.5 mM EDTA; 2.5% FCS in deionised water 
 
2.2.2.2 Automated magnetic cell sorting (autoMACS)  
Binding Buffer             0.5% FCS in PBS 
Running Buffer  2 mM EDTA; 0.5% FCS in Phosphate-buffered     
saline (PBS, Gibco, Germany)  
Rinsing Solution    2 mM EDTA in PBS 
Cleaning Solution   70% v/v ethanol 
 
2.2.2.3 SDS-PAGE, Western Blotting and EMSA  
Sample Buffer Bromo Phenol Blue (0.05% w/v); Glycerol (1 ml); 
Solution B (see Table 3; 1:5 dilutions) 
Sample Buffer Mix  β-Mercaptoetanol (200 µl); Sample Buffer (200 µl); 
10% SDS (400 µl); 10 M Urea (500 µl) 
Running buffer                                 Solution B (see Table 3; 1:5 dilution) 
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Western Blot Tank Buffer 39 mM Glycine; 20% Methanol; 0.0375% SDS; 48 
mM Tris;  
TBS (pH 8.0) 0.0027 M KCl; 0.138 M NaCl; 0.05 M Tris 
TBST (pH 8.0) TBS with 0.05% Tween-20  
TBE (0.5x, pH 8.2) 45 mM Boric Acid; 20 mM EDTA (pH 8.0); 45 mM 
Tris-HCl 
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2.3 Cell culture methods 
2.3.1 Human models 
2.3.1.1 Healthy human subjects 
Fifteen healthy human volunteers with an age range from 27-40 years were included in 
the study. All the volunteers gave their informed consent to donate blood for the 
experiments. 
 
2.3.2 Isolation and culture of various human cells 
2.3.2.1 Isolation and culture of human peripheral blood mononuclear cells  
Blood was drawn from healthy individuals and peripheral blood mononuclear cells 
(PBMC) were isolated by Ficoll (Biochrom, Berlin, Germany) density gradient 
centrifugation (550 x g, 30 min at room temperature) and washed twice (300 x g, 10 min 
at room temperature) with PBS. To enrich the monocytes, PBMC were resuspended and 
allowed to adhere, in tissue culture flasks for 3 h before nonadherent cells were removed 
by washing with PBS. Adherent cells were cultured overnight in RPMI 1640 medium 
supplemented with 2% human AB+ serum before stimulation was started. This procedure 
resulted in >80% monocytic cell purity as confirmed by FACS analysis using CD14 
staining. 
PBMC were seeded at a density of 1 x 107 in tissue culture flasks or 4 x 105 cells/200 
µl/well in 96-well flat bottom microtiter plates for signaling and cytokine analysis 
respectively. The isolated monocytes were incubated with or without 10 ng/ml 
recombinant human GM-CSF. After 6 h, GM-CSF was removed by medium exchange. 
For the control incubations, the medium was exchanged at the corresponding time point. 
The cells were further incubated in the presence or absence of 10 ng/ml LPS from 
Salmonella friedenau (phenol-extracted protein- and DNA-free LPS, kindly provided by 
H. Brade, Forschungsinstitut Borstel, Germany). The LPS stimulation was given for 45 
min to the cells in tissue culture flasks for the analysis of signaling molecules and in 96-
well plate for 4 h for cytokine analysis. 
 
2.3.2.2 Culture of human monocytic THP-1 cells 
THP-1 is a human monocytic cell line, derived from a human acute monocytic leukemia 
patient and was obtained from DSMZ, Braunschweig, Germany. Cells were cultured in 
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RPMI 1640 medium containing 10% of FCS (Sigma) in 60 mm Petri-dishes and used for 
the experiments. 
To analyze the various cytokine production, THP-1 monocytes (2 x 105 cells/200 
µl/well) were seeded in 96-well flat bottom microtiter plate for overnight and next day, 
the cells were stimulated with or without 10 ng/ml (also with different doses to determine 
the dose concentration) recombinant human GM-CSF (Molgramostin, Leucomax) for 
different time periods as indicated in the figure legends. After 6 h, GM-CSF was 
removed by medium exchange and the cells were stimulated with different doses of LPS 
(1-100 µg/ml) from Salmonella abortus equi (Sigma) for additional 4 h. Afterwards 
supernatants were collected, stored at -20°C until cytokine detection. For analysis of 
different signaling molecules, corresponding incubations with or without GM-CSF were 
set up in 60 mm Petri-dishes and the cells were stimulated with or without 10 µg/ml LPS 
for 45 min and used for further analysis. 
 
2.3.3 Mouse models 
2.3.3.1 Mice 
Both male and female BALB/c mice and male C57BL/6 mice were purchased from 
Harlan Winkelmann, Borchen, Germany. Male and female D011.10 TCRtg transgenic 
mice were bred in our own animal facility. All mice weighed up to 20-30 g, 6- 8 weeks 
old, were housed in sound-proof holding room at an ambient temperature of 24.0 ± 0.5°C 
under 12 h light/dark cycle. The mice had free access to standard lab chow and tap water 
ad libitum. All mice were allowed to habituate to the animal laboratory conditions for 
one week before starting the experiments. All animal experiments were carried out 
according to the German animal protection law and were approved by the 
“Bezirksregierung” Duesseldorf, Germany.  
 
2.3.3.2 Hemorrhagic shock  
For the induction of hemorrhagic shock, mice were anaesthetized by an intramuscular 
(i.m.) injection of 100 mg/kg body weight of Ketamine Hydrochloride (CEVA, Sante 
Animale, Duesseldorf, Germany) and 10 mg/kg Xylazin (CEVA, Sante Animale) after 
inhalation of Isoflurane. Mice were placed in supine position, a groin incision was 
performed, the femoral artery was aseptically cannulated with a 24-Gauge polyethylene 
tubing (Introcan, Braun-Melsungen, Germany) using minimal dissection technique. The 
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catheter was connected to a blood pressure analyzer (Combitrans Monitoring-Set, Modell 
II, Art. Nr. 05201675; Braun Melsungen, AG) and hemorrhage was started by blood 
withdrawal over the same catheter until the mean arterial pressure (MAP) of 50 ± 5 mm 
Hg was reached. The hemorrhagic shock was maintained for 35-40 min before 
resuscitation was started with the shed blood 1:2 diluted (anticoagulated with heparin) 
with warm (37oC) Ringer-solution. After reperfusion the catheter was removed, the 
femoral artery was ligated and the groin incision was closed. The animals were allowed 
to awake and were returned to their cages. Control animals were anaesthetized and 
operated correspondingly; the femoral artery surgically prepared and the vessel was 
ligated (sham operation).  
 
2.3.3.3 Cecal ligation and puncture 
For induction of polymicrobial sepsis, the cecal ligation and puncture (CLP) model 
(Figure 7) developed by Chaudry et al. [146] was used, with some modifications. Mice 
were anaesthetized by an intramuscular (i.m.) injection of 100 mg/kg body weight of 
animal Ketamine (CEVA, Sante Animale) and 10 mg/kg Xylazin (CEVA, Sante 
Animale) after inhalation of Isoflurane. Mice were placed in supine position and 1 cm 
incision was made for mid-line laparotomy (Figure 7, Panel 1). The cecum was exposed 
(Figure 7, Panel 2) and ligated (Figure 7, Panel 3) at half of the cecum length with 5-0 
silk suture (Ethicon, Norderstedt, Germany) and was punctured (Figure 7, Panel 4) once 
with a 17-Gauge needle (Klinika, Usingen, Germany). A small amount of cecum 
contents was extruded (Figure 7, Panel 5) through the puncture and the cecum was 
replaced into the peritoneal cavity. One ml of 0.9%  sodium chloride (Delta Select, 
Dreieich, Germany) was given intraperitoneally (i.p.) for resuscitation. The peritoneal 
wall and the skin were closed (Figure 7, Panel 6) in a double layer technique with 5-0 
silk sutures. Control animals were anaesthetized and operated correspondingly with 
laparotomy alone (sham operation). The CLP model led to severe polymicrobial sepsis 
with a mortality rate of 60-70% within 36 h of operation. 
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Figure 7. Cecal ligation and puncture model  
              Figure adapted from Hubbard et al. [147] 
 
  
2.3.3.4 Serum collection 
Blood was drawn from healthy BALB/c mice. The mice were dissected and opened from 
the upper part of the diaphragm, the heart was punctured with scissor and the blood was 
collected. The blood was kept at room temperature for 15 min for clotting, centrifuged at 
1100 x g for 10 min at 4°C and the serum was collected and stored at -20°C until further 
use. 
 
2.3.4 Isolation, purification and culture of various murine cell types 
2.3.4.1 Preparation and culture of peritoneal macrophages 
For the isolation of peritoneal macrophages, 5 ml ice cold RPMI 1640 medium was 
injected into the peritoneal cavity and was aspirated after 2 min under sterile conditions. 
The cells were then centrifuged (300 x g, 10 min, 4°C), resuspended in ice cold RPMI 
1640 medium until further use.  
To analyze the cytokine production, peritoneal macrophages (1 x 105 cells/200 µl/well) 
were seeded in 96-well flat bottom microtiter plate for 3 h and non-adherent and non-
viable cells were removed thereafter in order to enrich peritoneal macrophages. The 
macrophages were incubated overnight and the next day, cells were stimulated with or 
without 10 ng/ml recombinant murine GM-CSF (Sigma). After 6 h, GM-CSF was 
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removed by medium exchange and the cells were stimulated in the presence or absence 
of 1 ng/ml LPS from Salmonella friedenau for 4 h. Afterwards supernatants were 
collected, stored at -20°C and later on used for cytokine detection. For analysis of 
different signaling molecules the peritoneal cells were washed once (818 x g, 5 min, and 
4°C) and the cultures (1 x 106 cells/ml) were set up in RPMI 1640 medium with 10% of 
FCS (Sigma) in 60 mm Petri-dishes. After 3 h, the non-adherent and non-viable cells 
were removed by vigorously pipetting in order to enrich peritoneal macrophages. These 
macrophage cultures were incubated with and without 10 ng/ml GM-CSF for 6 h before 
cells were stimulated in the presence or absence of 1 ng/ml LPS (Salmonella friedenau) 
for 45 min and used for further analysis. 
 
2.3.4.1.1 Preparation of Bacteria  
Peritoneal lavage containing the bacterial flora was collected from both sham and septic 
mice using 1 ml PBS. The bacterial flora was cultured in 25 ml BacTec medium (BD, 
Biosciences) and optical density (OD) was measured at different time points until a 
plateau phase was reached. The bacterial cells were harvested, centrifuged (6500 x g, 15 
min, and 4°C) and resuspended in 100 µl of PBS. Thereafter, the bacteria were heat 
inactivated at 80°C for 15 min and stored at -80°C until further use. 
 
2.3.4.1.2 Macrophage viability test using MTT 
To check viability of the enriched macrophages and to rule out changes in the total 
amount of adherent macrophages caused by the experimental design, a viability test was 
performed after stimulation and removal of the supernatants. Therefore, cells were 
incubated with 100 µl RPMI 1640 with 1 mg/ml of the tetrazolium salt MTT (Sigma) 
which is reduced to formazan by the activity of mitochondrial dehydrogenases. After 3 h 
of incubation and cell lyses with isopropanol formazon formation was measured at 550 
nm with a reference wavelength of 690 nm. 
 
2.3.4.2 Preparation and culture of total spleen cells  
Total spleen cells (TSC) were prepared by collagenase digestion using 0.02 U/ml 
Blendzyme 2 (Section 2.2.2, Roche, Grenzach-Wyhlen, Germany) at 37˚C for 18 min. 
Spleens were meshed through a cell strainer (70 µm, BD Biosciences) into a Petri-dish 
and were transferred into a falcon tube by passing through a different cell strainer (40 
µm, BD Biosciences) and incubated in culture medium containing 5 mM EDTA for 5 
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min for dissociation of cell clusters. The cells were collected and resuspended in 500 µl 
of ammonium chloride lysis buffer (Section 2.2.2) per spleen, to lyse the red blood cells 
(RBC). The cells were mixed gently, 5 ml of culture medium was added and the cells 
were underlain thereafter with 2 ml of FCS and centrifuged (300 x g, 10 min, and 4°C). 
After washing, total spleen cells (TSC) were counted and used for further experiments.  
TSC (0.5 x 106 cells/500 µl/well) were cultured in culture medium in 48-well plates with 
or without GM-CSF (10 ng/ml), CpG (5 µg/ml) and IFN-γ  (10 ng/ml) for 18 h. Non-
adherent cells were harvested and used for IL-12 intracellular staining. 
 
2.3.4.3 Preparation of lymph node cells  
Popliteal lymph nodes were isolated and flushed with culture medium using a 27-Gauge 
needle. Remaining tissue was minced through a cell strainer (40 µm, BD Biosciences). 
After pooling, lymph node cells (LNC) were incubated in culture medium containing 2 
mM EDTA in order to dissociate cell clusters and were used for the cultures. Isolated 
LNC were used for FACS staining. 
 
2.3.4.4 Generation and culture of mouse bone marrow cells 
Bone marrow-derived dendritic cells were generated using the procedures of Lutz et al. 
[148]. Mice from healthy, sham and septic groups were euthanized by cervical 
dislocation; femurs and tibiae were removed and cleaned of tissue, and sterilized in 70% 
ethanol for 1 min and washed with PBS twice. Both ends of each bone were cut, and the 
marrow was flushed with culture medium (using a 27-Gauge needle). The bone marrow 
cells (BMC) were mixed to disrupt the cell aggregates and RBC were lysed with an 
ammonium chloride lysis buffer (Section 2.2.2). The cells were centrifuged (300 x g, 10 
min, and 4°C), washed and counted. BMC were seeded at a density of 2 x 106 in 100 mm 
Petri-dish (Falcon, BD Biosciences) in 10 ml of culture medium containing 20 ng/ml 
murine recombinant GM-CSF. Ten ml of culture medium containing 20 ng/ml murine 
recombinant GM-CSF was added to the plates after 3 d of culture. On d 7, nonadherent 
and loosely adherent cells were harvested, washed in PBS, counted and used for further 
experiments. The non-adherent cells on d 7 were termed as bone marrow derived 
dendritic cells (BMDC) and were 70-80% positive for the DC marker CD11c as 
confirmed by FACS analysis.  
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BMC on d 0 and BMDC on d 7 were counted and cultured (0.5 x 106 cells/500 µl/well) 
in 48-well plates with Bacterial lysate (different dilutions), CpG (5 µg/ml), LPS (10, 100 
and 1000 ng/ml), LPS (100 ng/ml) + CD40L (2.5 µg/ml) or PGN (3 µg/ml). The 
supernatants were collected after 18 h and stored at -20°C until analysis for different 
cytokine ELISA.  
 
2.3.5 Isolation and purification of various cell types using automated 
magnetic cell sorting (auto-MACS) 
2.3.5.1 Principle 
MACS Technology is based on MACS MicroBeads and automated MACS separator 
(Figure 8), and MACS columns. MACS MicroBeads are super-paramagnetic particles 
coupled to highly specific monoclonal antibodies and are used to magnetically label the 
target cell population. When MACS columns are placed in a MACS separator, the 
MACS column matrix provides a magnetic field strong enough to retain the labeled cells. 
Cells of interest (positive selection) or to be depleted (negative selection) are labeled 
with the specific magnetic beads and retained on the column. Unlabeled cells pass 
through and can be collected as the unlabeled fraction. The retained cells are eluted from 
the MACS column after removal of the magnetic field. The purity of the separated cells 
is generally 90-99%.  
                                           
 
 
 
 
 
 
 
 
 
 
 
Figure 8. autoMACS Separator. 
View at a glance (left) and an open view (right) 
 
 
2.3.5.2 Isolation of splenic dendritic cells and bone marrow derived dendritic cells  
Isolated TSC or BMDC were centrifuged (300 x g, 10 min, 4°C) and the cells were 
resuspended in 500 µl of binding buffer (Section 2.2.2) per 108 cells (same volume of 
buffers and reagents for fewer cells also but scaled up accordingly if the cells exceeded 
more than 108). Then 50 µl of MACS Basic MicroBeads (pre diluted as 1:10 in binding 
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buffer) were added to the cell suspension and mixed gently and thoroughly for few sec. 
The cells were washed by adding 12-15-fold volume of binding buffer, centrifuged and 
resuspended in 500 µl of binding buffer and proceeded for negative depletion (to remove 
unwanted materials and cells e.g. RBC) using auto MACS depletion program (possel). 
The negative unlabeled fraction was collected, counted and used for the isolation of 
CD11c+ cells. 
The negative cells were adjusted to 108 cells/400 µl in binding buffer. 100 µl of CD11c+ 
MACS MicroBeads per 400 µl of cell suspension were added, mixed gently and 
thoroughly and incubated for 15 min in the dark at 4°C with intermittent shaking of the 
cells every 5 min. The cells were washed by adding 12 to 15-fold volume of binding 
buffer, centrifuged and resuspended in 500 µl of binding buffer and proceeded for 
positive selection (to select the cells of interest) using the autoMACS positive selection 
program (posseld). The positive fraction (containing purified DC) was collected, 
centrifuged and resuspended in culture medium. The purified DC (generally 85-90% 
purity as confirmed by CD11c staining by FACS analysis) were counted and used for 
further experiments.  
Purified splenic DC were cultured in culture medium containing 0.3 ng/ml GM-CSF in 
the absence or presence of additional 10 ng/ml GM-CSF and 5 µg/ml CpG in 96-well flat 
bottom plates (1 x 105 cells/well). After 18 h, supernatants were collected and stored at-
20°C until analysis for different cytokine ELISA. Purified BMDC harvested on d 7 
(BMDC) were used in titrated amounts for in vitro T cell assay (described later, Section 
2.3.8.1). 
 
2.3.5.3 Isolation of splenic T cells  
Splenic T cells were isolated using Pan T cell isolation kit (Miltenyi), according to the 
manufacturer’s instructions. Non-T cells, i.e. B cells, NK cells, dendritic cells, 
macrophages, granulocytes and erythroid cells were indirectly magnetically labeled by 
using a cocktail of biotin conjugated cell specific antibodies and anti-biotin MicroBeads. 
Isolation of highly pure T cells was achieved by depletion of magnetically labeled cells. 
Therefore, isolated TSC including RBC (as described above) were centrifuged (300 x g 
for 10 min at 4°C) and resuspended in 400 µl of binding buffer per 108 cells (same 
volume of buffers and reagents for fewer cells also but scaled up accordingly if the cells 
exceeded more than 108). First, 100 µl of the biotin-antibody cocktail against CD45R 
(B220), DX5, CD11b (Mac-1) and Ter-119 was added to the cells, mixed and incubated 
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for 10 min in dark at 4°C and then 300 µl of binding buffer followed by 200 µl of anti-
biotin MicroBeads were added, mixed and incubated for additional 15 min in the dark at 
4°C. The cells were washed by adding 12-15-fold volume of binding buffer, centrifuged 
and resuspended in 500 µl of binding buffer and proceeded for depletion (to remove 
unwanted non-T cells) using autoMACS depletion program (deplete). The negative 
unlabeled fraction (containing purified T cells) was collected, centrifuged and 
resuspended in culture medium. The purified T cells (>90% purity as confirmed by 
FACS analysis) were counted and used for further experiments. 
 
2.3.6 Labeling of cells  
2.3.6.1 Carboxyfluorescein diacetate, succinimidyl ester labeling of T cells 
(Cell proliferation tracking by flow cytometry) 
Carboxyfluorescein diacetate, succinimidyl ester (CFDA SE, also called CFSE) staining 
is a simple and sensitive method that permits the study of specific populations of 
proliferating cells and the identification of 7-10 successive cell generations. CFDA SE is 
a fluorescein molecule containing a succinimidyl ester functional group and two acetate 
moieties. CFDA SE is a non-fluorescent dye that diffuses into the cytoplasm of cells. 
There the dye is cleaved by intracellular esterases and becomes highly fluorescent amine-
reactive product and forms dye-protein adducts that are not transferred to adjacent cells 
(Figure 9). The dye is retained by the cells throughout their development and is inherited 
equally by daughter cells after division, resulting in the sequential halving of mean 
fluorescence with each generation. When analyzed by flow cytometry, this sequential 
halving of fluorescence is visualized as distinct peaks and can be used to track division 
progression. Application includes analysis of cell division by flow cytometry for in vitro 
and in vivo studies.  
 
 
 
 
 
 
 
 
 
Figure 9. Mechanism of cellular labeling by CFDA SE.  
CFDA SE is a non fluorescent molecule that spontaneously penetrates cell membranes and is converted to 
a fluorescent CFSE by intracellular esterases. Amine-reactive coupling of CFSE to proteins results in 
stable long-term intracellular retention.  
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The Vybrant CFDA SE Cell Tracer Kit (Molecular Probes, Göttingen, Germany) was 
used for the analysis of non-specific and antigen-specific T cell proliferation, both in 
vitro and in vivo. Isolated T cells (4-8 x106 in 500 µl) were centrifuged (300 x g, 10 min, 
and 4°C) and resuspended in prewarmed PBS. CFDA SE stock solution (10 mM) was 
prepared by dissolving it in DMSO and the appropriate amount of CFDA SE (0.5 and 1.5 
µM for in vitro and in vivo T cell assay respectively) was added to the T cells. The cells 
were mixed well and incubated for 12 min at 37˚C in a water bath, centrifuged (300 g, 6 
min, room temperature), resuspended in 1 ml of fresh prewarmed medium and again 
incubated for 30 min at 37˚C. The cells were then centrifuged again and resuspended in 
prewarmed medium (1 ml). The T cell number was determined and used for in vitro 
and/or in vivo study as described later. 
 
2.3.7 Analysis of cells (Flow Cytometry) 
Flow cytometry was used for the analysis of various cells e.g. BMC, BMDC, splenic DC 
and TSC. Single cells were prepared and stained for surface markers and intracellular 
cytokines and was analyzed using flow cytometry. 
 
2.3.7.1 Principle 
Flow cytometry is a tool for the measurement (meter) of characteristics of single cells 
(cyto) as they flow through a series of detectors. A pressurized hydrodynamic focusing, 
laser beam(s), flow cell/laser intercept, a series of light detectors (PMTs) and a data 
analysis station are the main components of a flow cytometer. Cell samples in suspension 
pass through the sheath fluid under hydrodynamic pressure that makes the cells to flow 
in a defined stream of single file. The moving cell hits the focused beam of laser lights 
and the light is scattered in the forward direction (FSC, indicates size of the cell) and in 
the side direction (SSC, indicates contents and the granularity of the cell) with respect to 
the laser beam. This information is picked up by one of a series of photomultiplier tubes 
(PMTs) detectors and converted into a form suitable for computer storage and 
subsequent analysis (Figure 10) 
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               Figure 10. Schematic diagram of Flow Cytometry 
 
2.3.7.2 Cell surface and intracellular staining  
For the staining of cell surface markers, single cells (1 x 106) were prepared and 
transferred to 96-well-round bottom plate. The cells were washed (400 x g, 6 min, and 
4°C) in Cell Wash (BD Biosciences). The cells were resuspended in 50 µl of Cell Wash 
containing Fc block (1 µg, BD Biosciences) for blocking unspecific binding and 
incubated on ice for 6 min. Then, 50 µl antibody mixture (Table 2) containing anti-
CD11c (APC) in combination with anti-IAd (FITC, Biotin), anti-CD8 (FITC), anti-CD4 
(PE), anti-TLR4 (PE), anti-Gr1 (FITC), anti-CD11b (PerCPCy5.5), anti-CD40 (FITC), 
anti-CD86 (PE) was added. Anti-CD45 (FITC) was used in combination with anti-CD14 
(PE). For the staining of blood cells, antibodies were added directly to the blood and 
incubated for 15 min either in normal FACS tubes or TruCount tubes (BD Biosciences), 
for the determination of absolute counts of leukocytes in blood. After 15 min on ice, cells 
were washed and resuspended in Cell Wash. For intracellular staining, cells were 
stimulated and incubated for the last 4-6 h in the presence of monensin (GolgiStop 0.66 
µl/ml, BD Biosciences). After surface staining using anti-CD11c (APC) or anti-CD4 
(FITC) antibodies, cells were fixed and permeabilized using Cytofix/Cytoperm (BD 
Biosciences) for 20 min at room temperature in the dark and centrifuged. After washing 
twice with permeabilization buffer (BD Biosciences), intracellular cytokines were 
stained using anti-IL-12p40 (PE) or anti-TNF-α (PE) antibodies and washed again for 
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two times. The cells were resuspended in Cell Wash at the last step. Appropriate isotype 
controls were used for all staining. All data were acquired using a FACScalibur (BD 
Biosciences) and analyzed using Cell Quest Pro software (BD Biosciences). If possible, 
the FL-3 channel was used to exclude autofluorescent cells. Living cells were selected 
according to forward- and side-scatter properties. Total BMC, BMDC number per mouse 
was calculated as % CD11c cells x total number of cells per bone marrow/100. 
 
2.3.7.3 Staining for in vitro and in vivo T cell proliferation assay 
For in vitro T cell proliferation, the adherent cells were harvested and transferred to 96-
well-round bottom plate. The cell clusters were dissociated through addition of cluster 
dissociation buffer (Section 2.2.2) for 20 min at room temperature. After washing (400 x 
g, 5 min, and 4°C) with Cell Wash, the proliferated T cells (CFSE-labeled) were stained 
using anti-CD4 (PE) antibody (BD Biosciences). A constant number of CaliBRITE APC 
beads (BD Biosciences) were added to allow the acquisition of equal parts per culture. In 
order to exclude the dead cells, 7-Amino-actinomycin D (7-AAD; 4 µg/ml, Molecular 
Probes) was used. For data acquisition, a constant number of 10,000 CaliBRITE APC 
beads were counted. Living CD4+ T cells (CD4+ 7-AAD-) were gated, and the T cell 
proliferation was determined.  
For in vivo T cell proliferation, the LNC were stained for proliferated T cells (CFSE-
labeled) using anti-CD4 (PE) antibody and anti-D011.10 TCR (APC). Proliferating T 
cells (CD4+D011.10+) were gated, and the number of divided cells, showing less than the 
maximal CFSE fluorescence intensity, was determined.  
 
2.3.8 Cell proliferation assay 
2.3.8.1 In vitro allogenic T cell assay 
The titrated amounts of purified BMDC (2 x 104 - 0.065 x 104 cells) from BALB/c mice, 
in 200 µl/well were seeded in 96-well-flat bottom plates in triplicates. Purified splenic T 
cells from C57BL/6 mice were labeled with CFSE, counted and added (2 x 105 T 
cells/well) to the plated BMDC. After d 3, the supernatants were collected and stored at -
20°C for the analysis of cytokines by ELISA. The adherent cells were harvested and 
stained using fluorescent antibodies and the proliferation was determined by FACS 
(Section 2.3.7.3). 
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2.3.8.2 In vivo T cell assay  
DO11.10 TCR transgenic mice that encode a T cell receptor that is specific for a chicken 
ovalbumin (OVA) peptide, amino acids 323-339, presented by the MHC class II 
molecule, were used to determine in vivo T cell activation. Splenic T cells were purified 
from the transgenic mice and were labeled with CFSE (1.5 µM). T cells (5 x 106/100 µl 
PBS) were injected intravenously (i.v.) into the tail vein of a healthy, female BALB/c 
mouse. After 24 h, BMDC (2 x 106/2 ml/well) were stimulated in 6 well plates with 100 
µg/ml ovalbumin (OVA, Sigma) in the presence or absence of CpG (5 µg/ml) for 7 h. 
After washing twice, 0.5 x 106 BMDC, in a volume of 30 µl PBS, were then injected into 
the foot pad of BALB/c mice which had received the T cells, from the transgenic mice, 
the day before. Three days later, the mice were sacrificed, draining (popliteal) lymph 
nodes (LN) were harvested and the lymph node cells (LNC) were prepared as described 
earlier (Section 2.3.4.3). The LNC were used for the determination of T cell proliferation 
by using FACS (Section 2.3.7.3). Further, the isolated LNC were cultured (4 x 105 
cells/200 µl/well) in 96-well, flat bottom plate and restimulated with 10 and 50 µg/ml 
ovalbumin and 0.1 and 1 µg/ml ova peptide (OVA 323-339, MoBiTec) in triplicates. 
After 3 d, the supernatants were collected and used for cytokine ELISA.  
 
2.3.9 Enzyme linked immunosorbent assay  
Sandwich enzyme linked immunosorbent assay (ELISA) was used for the detection and 
quantification of cytokines secreted into different human and mouse cell culture 
supernatants. Capture antibodies were coated onto plastic 96-well microtiter plates, 
which were noncovalently adsorbed primarily as a result of hydrophobic interactions. 
The plates were blocked to avoid non-specific bindings and unbound materials were 
washed away. The captured cytokine proteins were detected using biotin-conjugated 
detection antibodies followed by an enzyme-labeled streptavidin step. The chromogenic 
substrate tetramethylbenzidine (TMB) was added and the level of colored product 
generated by the bound, enzyme-linked detection reagents was measured 
spectrophotometrically using an ELISA-plate reader at an OD of 450 nm with the 
reference OD at 570 nm. The concentration of different cytokines was measured using 
serial dilution of specific cytokine standards of known concentrations. Different ELISA 
kits were purchased from Beckman Coulter Company (Human IL-6, IL-8 and TNF-α), 
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Krefeld; Biosource (TNF-α), Solingen; and R & D Systems (Mouse IFN-γ, IL-2, IL-10, 
IL-12p40, IL-12p70 and TGF-β1), Weisbaden, Germany. 
 
2.4 Protein Chemical Methods 
2.4.1 Cytoplasmic and nuclear protein extraction  
Cytoplasmic and nuclear proteins were extracted by using ‘NE-PER Nuclear and 
Cytoplasmic Extraction Reagent’ Kit (Pierce, Perbio, Bonn, Germany). After LPS 
stimulation, the cell layer was washed with ice cold PBS containing 0.5% NaVO3. Cells 
were scraped off from the culture flasks or the Petri-dishes using a rubber policeman cell 
scraper (Nunc, Wiesbaden, Germany) and centrifuged (200 x g, 10 min, 4°C). The cell 
pellet was resuspended in Cytoplasmic Extraction Reagent (CER) with a set of protease 
inhibitors (Pierce) for 10 min on ice. The cells were centrifuged (12000 x g, 5 min, and 
4°C) and the supernatants containing cytoplasmic proteins were collected. The cell pellet 
containing the nuclear proteins was resuspended in Nuclear Extraction Reagent (NER) 
for 15 min on ice and centrifuged (12000 x g, 10 min, and 4°C). The supernatants 
containing nuclear proteins were collected. Both cytoplasmic and nuclear extracts were 
stored at -80°C until further use. 
 
2.4.2 Determination of protein concentration 
The BioRad DC Protein Assay kit was used to determine the protein concentration of 
cytoplasmic and nuclear protein extracts following the manufacturer’s instructions. 
Protein concentration was measured with a spectrophotometer at an optical density (OD) 
of 700 nm. BSA was used as a standard with a detection limit of 16 pg/ml.  
 
2.4.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate out the proteins on the basis of size from the cytoplasmic protein extracts. 
Protein samples were prepared using the sample buffer mix (Section 2.2.2) in 1:1 ratio 
with sample by boiling for 5 min at 95˚C. Ten to fifty micrograms of proteins were 
subjected to 10% SDS-polyacrylamide gel (composition as described in Table 3) and run 
at 120 V (constant voltage) until the dye front reached the bottom. Pre-stained SDS-
PAGE standard (BioRad Laboratories) was used to know the molecular weight of 
different proteins.  
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Table 3. Composition for the preparation of 10% polyacrylamide gel 
Solution 10% 
A. 22.2% (w/v) Acrylamide; 0.6%(w/v) N,N-Methylene-Bis-Acrylamide 6.3 ml 
B. 0.5 M Tris; 0.5 M N,N- Bis-(Hydroxyethyl)-Glycine (Bicine, C6H13NO4)    4 ml 
C. 10 M Urea    6 ml 
Distilled H2O 2.7 ml 
D. TEMED   15 µl 
E. APS, 15 mg/ml     1 ml
 
2.4.4 Western blot analysis of MAPK and IκBα  
The proteins, separated by SDS-PAGE, were transferred from the gel onto nitro-cellulose 
membranes (BioRad Laboratories) using Hoefer wet electro-transfer system. Membranes 
were blocked with blocking solution (Roche Diagnostics, Mannheim, Germany) for 1 h 
at room temperature, washed 5 times for 5 min each using Tris Buffered Saline with 
Tween-20 (TBST) and incubated with the respective primary antibodies (Cell Signalling 
Technology, Frankfurt, Germany) for various MAPK and IκBα for overnight at 4°C. 
IκBα and phosphorylated IκBα were detected using a 1:1500 dilution. P-ERK1/2 
(1:1500), ERK1/2 (1:1500), P-P38 (1:800), P38 (1:800) were detected using antibodies 
reacting specifically with the phosphorylated or the unphosphorylated forms of the 
proteins. The primary antibody against the phosphorylated IκBα was specific for the 
detection of the phosphorylated serine 32 residue, while the phosphorylated-specific 
MAPK antibody detected the phosphorylated threonine 202 and tyrosine 204 residues of 
ERK1/2 and threonine 180 and tyrosine 182 of P38MAPK. The membranes were 
incubated with a secondary antibody (peroxidase-conjugated goat anti-rabbit IgG) for 1 h 
at room temperature (Roche Diagnostics). After 5 washes with TBST, the blots were 
developed using chemiluminescence horseradish peroxidase substrate (Roche 
Diagnostics) for 5 min and were exposed to x-ray films (Kodak, Stuttgart, Germany). 
Loading controls for each signaling molecule were carried out on the same membranes 
after analyzing the phosphorylated proteins and stripping using a restore western blot 
stripping buffer (Pierce) for 30 min at 37˚C and secondary western blot with antibodies 
detecting the total amount of the respective kinase. 
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2.4.5 Electrophoretic mobility shift assay  
Electrophoretic mobility shift assay (EMSA) is a technique for studying gene regulation 
and determining protein-DNA interactions. The assay is based on the observation that 
complexes of protein and DNA migrate through a non-denaturing polyacrylamide gel 
more slowly than free DNA fragments or double-stranded oligonucleotides, resulting in a 
“shift” in migration of the labeled DNA band. Double-stranded oligonucleotides (Santa 
Cruz Biotechnology, Heidelberg, Germany) containing the wild-type consensus DNA 
binding sequences for NFκB (5′-AGTTGAGGGGACTTTCCCAGGC-3′) were used. 
Labeling of oligonucleotides and EMSA was done according to the instructions of the 
biotin 3′-end DNA Labeling Kit and ‘LightShift Chemiluminescent EMSA’ Kit, 
respectively (Perbio Science).  
 
2.4.5.1 Labeling of oligonucleotides 
A concentration of 1 nmol/ml sense and anti-sense oligonucleotides was prepared using 
Tris-HCl Buffer (10 mM, pH8). On ice, 10 µl 5x reaction buffer, 5 µl of sense or anti-
sense oligonucleotide, 5 µl Biotin-N4-CTP, 5 µl of Terminal Deoxynucleotidyl 
Transferase (TdT, 2U/µl prepared in 1x reaction buffer) and 25 µl H2O was mixed to 
have 50 µl reaction volume. The reaction mix was incubated for 30 min at 37˚C. Then 
2.5 µl EDTA (0.2 M) was added to the reaction mix to stop the labeling reaction. 
Labeled sense and anti-sense oligonucleotides were mixed in 1:1 ratio (50 µl each), 
incubated for 1 h at room temperature and then stored at -20°C until further use. 
 
2.4.5.2 Binding reaction, gel run, transfer and detection of nuclear protein extracts  
Twenty micro liter of binding reaction per test sample, positive control and the 
competition reactions containing 3 µg of nuclear proteins was prepared (Table 4), and 
incubated for 20 min at room temperature. Loading buffer (5 µl of 5 x stock) was added 
to each binding reaction and was used for the electrophoresis. The DNA-protein samples 
were separated on 6% native polyacryamide gels at 100 V (constant voltage) in 0.5 x 
TBE (Section 2.2.2). After electrophoresis, gels were transferred to nylon membranes in 
an electroblotting unit (Transphor, LKB, Munich, Germany) in 0.5 x TBE, cooled to 
10˚C for 30 min with 380 mA. After transfer, the membranes were cross-linked at 120 
mJ/cm2 using a UV cross-linker (Biometra, Göttingen, Germany), blocked with 
‘LightShift’ (Perbio Science) for 15 min and then treated with streptavidin-horseradish 
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peroxidase conjugate for 15 min. After washing, the membranes were incubated for 5 
min in substrate equilibration buffer and for 5 min in an enhanced luminol substrate for 
horseradish peroxidase (HRP) and were exposed to Hyperfilm ECL films. 
 
Table 4. Preparation of Binding reactions  
Reactions   
Component 
  
Final Amount + ve Control  Test  Competition  
Ultrapure Water  --- 12 ml  ---  --- 
10 x Binding Buffer  1X 2 µl 2 µl 2 µl 
50% Glycerol  2.50% 1 µl 1 µl 1 µl 
100 mM MgCl2  5 mM  1 µl 1 µl 1 µl 
1 µg/µl Poly (dI•dC) 50 ng/µl 1 µl 1 µl 1 µl 
1% NP-40  0.05% 1 µl 1 µl 1 µl 
Unlabeled NF-kB (competition) 200 nmol/ml  ---  --- 2 µl 
Control DNA (Biotin-EBNA) 20 fmol 1 µl  ---  --- 
EBNA Extract 1 Unit 1 µl  ---  --- 
Protein Extract 3 µg  --- 3 µg 3 µg 
Biotin End-Labeled NF-kB DNA 1 nmol/ml  --- 2 µl 2 µl 
Total Volume  --- 20 µl 20 µl 20 µl 
 
 
2.5 Statistical Analysis 
For analysis of independent parameters between each individual group the Mann-
Whitney-U-test was used. For comparison of cultures with and without GM-CSF 
incubation a paired Wicoxon test was applied. The paired Student’s t-test was used to 
compare differences between sham and CLP groups. The unpaired Student’s t-test was 
used to compare differences between replicates of cell cultures within one experiment. 
Values are expressed either as mean and standard deviation (Mean ± SD) or mean and 
standard error of mean (Mean ± SEM) as indicated. A p-value ≤ 0.05 was considered to 
be significant. 
 
 
 44
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS
 
 
 
 45
  
 
3. Results 
 
3.1 Immunomodulation by GM-CSF 
 
3.1.1 Immunomodulation by GM-CSF in human monocytes 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a haematopoietic 
growth factor with immunomodulating activity. Besides its extensively studied role in 
differentiation and proliferation of monocytes and granulocytes, GM-CSF alters 
functions of mature monocytes and macrophages. So, GM-CSF potentiates the release of 
various cytokines such as TNF-α, IL-1α and IL-1β after LPS stimulation without 
inducing these mediators by its own [87, 88, 149]. Based on the growing interests in its 
immunostimulatory properties, the underlying mechanisms of GM-CSF on LPS-induced 
TNF-α secretion of human monocytes was examined. First, the optimal dose and time of 
GM-CSF in terms of priming of LPS-induced cytokine synthesis was analyzed in human 
monocytes.  
 
3.1.1.1 Time and Dose kinetics for GM-CSF  
In order to determine the optimal time and dose of GM-CSF for priming of TNF-α 
production by human monocytes, peripheral blood monocytes (PBMC) were incubated 
with different doses of GM-CSF for different time periods. Monocytes were stimulated 
for 4 h with LPS from S. friedenau, since former experiments had revealed a significant 
TNF-α secretion in the supernatant at this time point. The increased LPS-induced TNF-α 
synthesis caused by GM-CSF reached its maximum after a preincubation period of 6 h 
and remained stable up to  24 h (Figure 11A). Furthermore, the GM-CSF effect on TNF-
α synthesis revealed a dose dependency. The maximal response was observed at a dose 
of 100 ng/ml GM-CSF (Figure 11B). Based on these data, the further experiments to 
characterize and modulate GM-CSF priming for TNF-α and also IL-8 production by 
isolated monocytes were performed with a dose of 10 ng/ml and 6 h preincubation. The 
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dose of 10 ng/ml GM-CSF was chosen, since this was the peak level observed in 
pharmacokinetic studies in the clinical application of GM-CSF.  
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Figure 11. Time- and dose-dependent effect of GM-CSF on LPS-induced TNF-α production.  
(A) TNF-α production of monocytes expressed as mean ± SD of three independent experiments. The cells 
were preincubated with rhGM-CSF over different periods of time as shown and thereafter stimulated with 
10 ng/ml LPS for 4 h. Unstimulated samples served as controls (Med). (B) TNF-α production by 
monocytes expressed as mean ± SD of triplicate experiments. The cells were preincubated with different 
doses of rhGM-CSF and thereafter 10 ng/ml LPS stimulation for 4 h.  
 
3.1.1.2 Effect of GM-CSF on LPS-induced TNF-α and IL-8 secretion of human 
monocytes 
With the above standardized time and dose conditions, GM-CSF increased the LPS-
induced TNF-α synthesis (Figure 12A) by a factor of 4.8 (range 2.3-5.9, n=14, p< 
0.0005 in Student’s T-test) and IL-8 synthesis (Figure 12B) by a factor of 2.6 (range 1.2-
5.6, n=14, p< 0.0005 in Student’s T-test). In none of these experiments, an increase of 
TNF-α secretion was observed after the preincubation with GM-CSF in the absence of 
LPS (Figure 12A). However, IL-8 synthesis was slightly increased upon GM-CSF 
preincubation alone (Figure 12B). 
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Figure 12. Increased TNF-α and IL-8 production after GM-CSF preincubation in human monocytes.  
(A) TNF-α  and (B) IL-8 production by monocyte cultures carried out in triplicates. Data shown is mean ± 
SD of indicated numbers of pooled experiments. The cells were preincubated with 10 ng/ml of rhGM-CSF 
for 6 h and thereafter stimulated with 10 ng/ml LPS for 4 h. Unstimulated samples served as controls 
(Med). ≠ indicates statistical significant difference to LPS vs. GM-CSF and * indicates statistical 
significant difference to GM-CSF+LPS vs. LPS for both TNF-α and IL-8 synthesis in Student’s T-test. n: 
number of independent experiments. ≠ and ***, P < 0.0005. 
 
3.1.1.3 Effect of GM-CSF priming on LPS-induced phosphorylation of IκBα and 
MAPKinases 
In order to analyze the signaling cascades involved in the GM-CSF-mediated priming of 
LPS-induced TNF-α synthesis, different MAPKinases and the phosphorylation of IκBα 
were detected by Western blotting. GM-CSF is known to activate various MAPKinases 
[114]. It has been shown that GM-CSF induces phosphorylation of MEK1/2 and ERK1/2 
in human neutrophils [114, 150]. In the present study, we observed the induction of 
ERK1/2 phosphorylation by LPS, however, to a much lesser degree than by GM-CSF 
alone. LPS stimulation after GM-CSF preincubation did not further increase the 
phosphorylation of these signaling molecules (Figure 13). The P38 MAPK was 
marginally induced by GM-CSF alone in monocytes. A clear induction was observed 
after LPS alone, but the most pronounced signal was shown in GM-CSF primed 
monocytes (Figure 13). The amount of unphosphorylated MAPkinases was affected 
neither by LPS nor by GM-CSF. Human monocytes preincubated with GM-CSF (10 
ng/ml) for 6 h and stimulated thereafter with LPS (10 ng/ml) for 45 min showed an 
enhanced phosphorylation of IκBα compared to LPS alone while GM-CSF on its own 
had no effect (Figure 13).  
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Figure 13. Effect of GM-CSF on phosphorylation of IκBα and MAPK.  
Western blot of 20 µg cytoplasmic protein extracts from isolated human monocytes after 6 h preincubation 
with or without GM-CSF. After preincubation, GM-CSF was removed, cells were washed twice with PBS 
and afterwards stimulated with LPS (10 ng/ml) for 45 min and compared to untreated (no GM-CSF, shown 
as Med) and unstimulated (no LPS, only preincubation with GM-CSF). The phosphorylated forms of 
ERK1/2, P38 kinase and IκBα are shown from the top to bottom of the figure as indicated. The total 
amount of each kinase as loading control is shown in the panel below the phosphorylated forms. A 
representative blot of three independent experiments is shown.  
 
3.1.1.4 Effect of GM-CSF on LPS-induced NFκB binding in the nucleus 
TNF-α gene activation depends on the binding of the NFκB transcription factor to its 
promoter in the nucleus. The binding of the transcription factor was analyzed by EMSA. 
Analysis was performed after preincubation with GM-CSF (10 ng/ml for 6 h) and 
subsequent LPS-stimulation (10 ng/ml) for 45 min. Former experiments revealed a 
maximal NFκB binding after 45 min of LPS stimulation. Electromobility shift assay 
showed that LPS alone caused binding of the transcription factor as expected (Figure 14, 
Lane 2). While GM-CSF in the absence of LPS did not increase NFκB binding 
compared to unstimulated controls (Figure 14, Lanes 1 vs. 3). However, corresponding 
to the enhanced TNF-α protein production after GM-CSF preincubation, an increased 
 49
NFκB binding was observed after GM-CSF preincubation and subsequent LPS 
stimulation (Figure 14, Lane 4). 
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Figure 14. Effect of GM-CSF priming on LPS-induced NFκB binding.  
EMSA with 3 µg nuclear protein extracts of human monocytes for NFκB oligonucleotides. The cells were 
preincubated with or without GM-CSF (10 ng/ml) for 6 h, washed twice with PBS and subsequently, 
stimulated with LPS (10 ng/ml) for 45 min. A representative blot of three independent experiments is 
shown.  
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3.1.2 Immunomodulation by GM-CSF in THP-1 cells 
After we observed the GM-CSF priming in LPS-induced human monocytes, we 
continued the same approach for THP-1 human monocytic cell line as a model for human 
peripheral blood monocytes (PBMC). We did the standardization experiment to know 
whether the dose and the time for THP-1 cells are same as observed in human PBMC. 
Afterwards, we continued to see the effect of GM-CSF on LPS-induced THP-1 
monocytes with regard to TNF-α synthesis and the involved signaling pathway. 
 
3.1.2.1 Time and Dose kinetics for GM-CSF 
 The time and the dose standardization of GM-CSF and LPS for priming of TNF-α 
production by human THP-1 cells were performed to determine their optimal dose and 
time. The cells were preincubated with different doses of GM-CSF and then were 
stimulated with LPS from S. friedenau. The optimal time for the maximum priming 
effect in LPS-induced TNF-α synthesis by GM-CSF was observed as early as after  90 
min and was stable up to 24 h (Figure 15A, shown only up to 6 h). The priming effect of 
GM-CSF was also dose dependent and the maximal response was observed at a dose of 
10 ng/ml GM-CSF (Figure 15B). Based on these data, all the further experiments were 
performed with a dose of 10 ng/ml GM-CSF for 90 min preincubation and subsequent 
LPS stimulation for 4 h.  
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Figure 15. Time- and dose-dependent effect of GM-CSF on LPS-induced TNF-α production.  
(A) TNF-α production by THP-1 cell cultures carried out in triplicates. Data shown is mean ± SD of 
indicated numbers of pooled experiments. The cells were preincubated with rhGM-CSF (10 ng/ml) at 
different time points as shown. After preincubation with GM-CSF, the cells were stimulated with 1 µg/ml 
LPS for 4 h. (B) TNF-α production by THP-1 cells expressed as mean ± SD of cell cultures carried out in 
triplicates after preincubation with different doses of rhGM-CSF for 90 min. After preincubation with GM-
CSF the cells were stimulated with 1 and 10 µg/ml LPS for 4 h. Unstimulated samples served as controls 
(Med). Data shown is representative of three independent experiments.  
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3.1.2.2  Effect of GM-CSF on LPS-induced TNF-α, IL-8 and IL-6 secretion by 
THP-1 cells 
Following the above shown standardized time and dose conditions, GM-CSF at a dose of 
10 ng/ml for 90 min preincubaion increased LPS-induced (1 µg/ml for 4 h) TNF-α 
synthesis (Figure 16A) by a factor of 2.5 (range 1.9-3.4, n=7, p< 0.005 in Student’s T-
test) and IL-8 synthesis (Figure 16B) by a factor of 2.4 (range 1.9-3.6, n=8, p< 0.0005 in 
Student’s T-test). In none of these experiments, an increase of TNF-α was observed after 
the preincubation with GM-CSF in the absence of LPS. We did not observe a significant 
IL-6 secretion in THP-1 cells neither after LPS alone nor with GM-CSF and subsequent 
LPS stimulations (Figure 16C). 
 
 
 
 
 
 
 
 
 
Figure 16. Increased TNF-α and IL-8 but unchanged IL-6 production by THP-1 cells after GM-CSF 
preincubation. 
 (A) TNF-α  (B) IL-8 and (C) IL-6 production by THP-1 cell cultures carried out in triplicates. Data shown 
is mean ± SD of indicated numbers of pooled experiments. The cells were preincubated with 10 ng/ml of 
rhGM-CSF. After 90 min, the cells were stimulated with 1 µg/ml LPS for 4 h. Unstimulated samples 
served as controls (Med).  ≠ indicates statistical significant difference to LPS vs. GM-CSF and * indicates 
statistical significant difference to GM-CSF+LPS vs. LPS for both TNF-α and IL-8 synthesis in Student’s 
T-test. n: number of independent experiments. ≠ and ***, P < 0.0005. 
 
3.1.2.3 Effect of GM-CSF priming on LPS-induced phosphorylation of IκBα and 
MAPKinases 
In order to analyze the signaling cascade involved in the GM-CSF-mediated priming of 
LPS-induced TNF-α synthesis in THP-1 cells, we examined different MAPKinases and 
the phopshphorylation of IκBα by Western blotting. Similar to human monocytes, 
phosphorylation of ERK1/2 in THP-1 cells was also induced by LPS, however, to a 
lesser degree than by GM-CSF alone. Unlike human monocytes, LPS stimulation after 
GM-CSF preincubation further increased the phosphorylation of these signaling 
molecules (Figure 17). The P38 MAPK was marginally induced by GM-CSF alone in 
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THP-1 cells. A clear induction was found after LPS treatment alone, but the most 
pronounced signal was observed in LPS-treated THP-1 cells preincubated with GM-CSF 
(Figure 17). JNK, another member of the MAP kinase family, also showed more 
pronounced phosphorylation after GM-CSF preincubation and LPS stimulation in 
comparison to LPS or GM-CSF alone (Figure 17). The amount of unphosphorylated 
MAPkinases was affected neither by LPS nor by GM-CSF (Figure 17). THP-1 cells, 
preincubated with GM-CSF (10 ng/ml) for 30 min and stimulated thereafter with LPS (1 
µg/ml) for 45 min showed an enhanced phosphorylation of IκBα compared to LPS alone, 
while GM-CSF on its own had no effect and was the same as the control signal (Figure 
17) which was accompanied by a corresponding opposite pattern of the total IκB protein 
as a step for protease-dependent degradation subsequent to phosphorylation. 
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Figure 17. Effect of GM-CSF on phosphorylation of IκBα and MAPK.  
Western blot of 25 µg cytoplasmic protein extracts from THP-1 cells after 90 min preincubation with or 
without GM-CSF. After preincubation, GM-CSF was removed, cells were washed twice with PBS and 
afterwards stimulated with LPS (1 µg/ml) for 45 min. The phosphorylated forms of ERK1/2, P38 
MAPKinase, JNK and IκBα are shown from the top to bottom of the figure as indicated. The total amount 
of each kinase as loading control is shown in the panel below the phosphorylated forms. The blot shown is 
representative of a minimum of three independent experiments.  
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3.1.2.4 Effect of GM-CSF on LPS-induced NFκB binding in the nucleus 
The binding of the transcription factor NFκB to its promoter was also analyzed in THP-1 
cells using EMSA. Analysis was performed after preincubation with GM-CSF (10 ng/ml 
for 90 min) and subsequent LPS-stimulation (1 µg/ml) for 45 min. EMSA results showed 
that LPS alone caused binding of the transcription factor as expected (Figure 18, Lane 
3), while GM-CSF alone did not induce any NFκB binding when compared to 
unstimulated controls (Figure 18, Lanes 1 vs. 2). However, corresponding to the 
enhanced TNF-α protein production after GM-CSF activation, an increased NFκB 
binding was observed after GM-CSF preincubation and subsequent LPS stimulation 
(Figure 18, Lane 4). Wild type (WT) unlabeled NFκB oligonucleotides were included 
for the competition reaction as negative control (Figure 18, Lane 5) 
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Figure 18. Effect of GM-CSF priming on LPS-induced NFκB binding.  
EMSA with 3 µg nuclear protein extracts of THP-1 cells for NFκB oligonucleotides. The cells were 
preincubated with 10 ng/ml GM-CSF (Lane 2) for 90 min. After preincubation, GM-CSF was removed, 
cells were washed twice with PBS and stimulated with LPS (1 µg/ml) for 45 min (Lane 4). Unstimulated 
samples served as controls (Lane 1). Wild type (WT) NFκB oligonucleotides were taken as the EMSA 
control (Lane 5). The blot shown is representative of a minimum of three independent experiments.  
 
3.1.2.5 Effect of GM-CSF on translocation of NFκB- p50 and p65  
NFκB consists of hetero (p50/p65) - or homodimers (p50/p50). Therefore, not only 
binding of the transcription factors but also the levels of the total protein amount of 
corresponding transcription factor NFκB subunits p50 and 65 were analyzed by Western 
blotting (Figure 19). The experiments were performed with a dose of 10 ng/ml GM-CSF 
for 90 min preincubation and with subsequent LPS-stimulation (1 µg/ml, 45 min). These 
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experiments revealed that GM-CSF preincubation plus LPS-stimulation leads to elevated 
nuclear levels of the NFκB component p65 and to a lesser degree of p50.  
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Figure 19. Effect of GM-CSF priming on LPS-induced translocation of p50 and p65.  
Immunoblots carried out with 25 µg nuclear protein extracts for the NFκB components p50 and p65 of 
human THP-1 cells after 90 min preincubation with or without GM-CSF. After preincubation GM-CSF 
was removed, cells were washed twice with PBS and afterwards stimulated with LPS (1 µg/ml) for 45 min. 
The blot shown is representative of a minimum of three independent experiments.  
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3.1.3 Immunomodulation by GM-CSF after hemorrhagic shock 
GM-CSF could successfully prime both the human monocytes as well as THP-1 cells up 
to a significant level for TNF-α synthesis after LPS stimulation. The cytokine synthesis 
was paralleled by a correspondingly enhanced MAPkinase and IκBα signaling. This 
immunostimulatory capacity of GM-CSF was then harnessed for an immunosuppressed 
system after hemorrhagic shock. Before proceeding for hemorrhagic shock model 
directly, the effect of GM-CSF was studied in peritoneal macrophages of normal 
untreated mice.  Afterwards, we continued to investigate the effect of GM-CSF on LPS-
induced peritoneal macrophages with regard to TNF-α synthesis and the involved 
MAPKinase and NFκB regulating IκBα signaling after hemorrhagic shock. 
 
3.1.3.1 Effect of GM-CSF in normal peritoneal macrophages 
3.1.3.1.1 Time kinetics for GM-CSF priming in normal peritoneal macrophages 
Characterization of GM-CSF effect was determined in normal peritoneal macrophages 
from untreated mice in terms of dose and time dependency.  GM-CSF priming for LPS-
stimulated TNF-α response was a time-dependent phenomenon. The effect started as 
early as after 1 h preincubation and further increased until a preincubation period of 6 h 
and stayed stable for at least 10 h (data not shown). Therefore, all further experiments 
were performed with a preincubation period of 6 h. The enhanced TNF-α response after 
6 h preincubation with GM-CSF and subsequent LPS stimulation showed a dose-
dependency also, both sensitizing macrophages for lower LPS doses and increasing the 
maximal response (Figure 20).  
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 Figure 20. Priming of TNF-α response 
after GM-CSF incubation. 
Peritoneal macrophages were pooled (2-3 mice) 
from normal mice and incubated in triplicates
for 6 h with different doses of GM-CSF as 
indicated in the figure and subsequently 
stimulated with the different LPS-doses shown 
on the x-axis for 4 h before TNF-α was 
detected in the supernatant. Data shown is 
representative of 3 independent experiments. 56
3.1.3.1.2 Effect of GM-CSF on TNF-α secretion in normal peritoneal macrophages 
With the standardized time and dose conditions of 10 ng/ml GM-CSF preincubation for 6 
h and subsequent 1 ng/ml LPS-stimulation for 4 h for mouse peritoneal macrophages, 
increased TNF-α synthesis (Figure 21) by a factor of 4.07 (range 1.6-10.7, n=10, p< 
0.0007 in Student’s T-test). However, increase of TNF-α production was observed in 
none of these experiments after the preincubation with GM-CSF in the absence of LPS.  
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Figure 21. Priming of TNF-α response after GM-CSF incubation 
Peritoneal macrophages were pooled (2-3 mice) and incubated in triplicates. The cells were preincubated 
with or without 10 ng/ml GM-CSF. After 6 h, the macrophages were stimulated with 1 ng/ml LPS for 4 h 
and the supernatants were collected for TNF-α ELISA.  Untreated samples served as the control (Med). 
Values are expressed as mean ± SEM of pooled experiments. ≠ indicates statistical significant difference to 
LPS vs. GM-CSF and * indicates statistical significant difference to GM-CSF+LPS vs. LPS for TNF-
α synthesis. n: number of independent experiments. ≠ and ***, P < 0.0005. 
 
3.1.3.1.3 Effect of GM-CSF priming on LPS-induced phosphorylation of IκBα and 
MAPKinases in normal peritoneal macrophages 
Before analyzing the signaling involved in the GM-CSF-mediated priming of LPS-
induced TNF-α synthesis after hemorrhagic shock, we analyzed untreated mice for 
different MAPKinase signaling cascade and the phosphorylation of IκBα by Western 
blotting. The increase in cytokine synthesis after GM-CSF preincubation led to a more 
intense activation of the signaling molecules ERK1/2, P38MAPK and IκBα at 45 min 
after LPS stimulation (Figure 22B). The priming effect of GM-CSF on 
IκBα phosphorylation and ERK1/2 activation was also visible at earlier time points of 
LPS stimulation (15 and 30 min, Figure 22A).  
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Figure 22. Elevated MAPKinase and IκBα phosphorylation after GM-CSF preincubation and 
subsequent LPS stimulation. 
(A) Peritoneal macrophages (pooled cells from 3 mice) were harvested from the normal healthy mice and 
preincubated with or without GM-CSF for 6 h and then stimulated for different time periods (15 and 45 
min) with LPS. Cytoplasmic proteins were extracted and P-ERK1/2 and P-IκBα were analyzed by Western 
blotting. Both P-ERK1/2 and P-IκBα were enhanced more after 45 min of LPS stimulation than that of 15 
min. (B) Peritoneal macrophages (pooled cells from 3 mice) were harvested from the normal healthy mice 
and incubated for 6 h with GM-CSF (10 ng/ml) and 45 min with LPS (1 ng/ml) along with their respective 
controls. Cytoplasmic proteins were extracted and IκBα, ERK1/2 and P38MAPK were analyzed by 
Western blotting using specific antibodies for phosphorylated IκBα, ERK1/2 and P38MAPK. The 
respective control antibody was used to detect the total amount of each kinase. GM-CSF enhanced LPS-
stimulated IκBα, P38 and ERK1/2 phosphorylation, while only ERK1/2 and to a lesser degree P38 were 
activated by GM-CSF on its own. The blot shown is representative for a minimum of three independent 
experiments. 
 
 58
3.1.3.2 Effect of GM-CSF after hemorrhagic shock 
It has been shown that GM-CSF renders the capacity to enhance monocytes’ and 
macrophages’ effector functions after shock as well as during sepsis [95-97]. GM-CSF is 
also reported to restore the reduced TNF-α production of splenic and peritoneal 
macrophages after hemorrhagic shock in rats [94]. On the basis of these 
immunostimulatory properties of GM-CSF, we also analyzed the effect of GM-CSF 
applied in vitro on peritoneal macrophages after hemorrhagic shock in mouse model. 
 
3.1.3.2.1 Hemorrhagic shock model characterization 
In the first set of experiments the blood pressure-dependent mortality of the hemorrhagic 
shock model was established. While a shock with a mean arterial pressure (MAP) of 35 
mm Hg for 45 min resulted in 100% mortality within 48 h, a MAP of 45 mm Hg for 45 
min caused 40% mortality. A MAP of 50 mm Hg caused only 20% mortality and after 55 
mm Hg no deaths were observed. The survival rate (%) and the corresponding withdrawn 
blood volumes are shown in Table 5. Since the primary scope of the study was to 
analyze the deterioration of the immune response after hemorrhagic shock, all further 
experiments were performed with 50 mm Hg shock.  
 
Table 5. Survival rate after hemorrhagic shock 
 
 
 
 
 
 
Survival rate is shown as percentage, 72 h after hemorrhagic shock with different mean arterial pressure. 
The corresponding withdrawn blood volume is indicated in the second row (mean ± standard deviation). 
Survival rate was calculated out of 10 animals per group. Survival after 72 h equals long term survival, 
since no animal died in the subsequent 4 weeks. 
 
3.1.3.2.2 Cytokine response in peritoneal macrophages after hemorrhage 
Hemorrhagic shock of 50 mm Hg MAP for 45 min leads to an impairment of the 
animals’ immune response after 20 h. Peritoneal macrophages isolated 20 h after 
hemorrhagic shock showed a significantly decreased production of TNF-α after in vitro 
stimulation with LPS in comparison to macrophages from sham-operated animals 
(Figure 23). 
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Figure 23. Decreased TNF-α production in LPS-stimulated cells.  
Peritoneal macrophages were harvested 20 h after hemorrhage (Shock) or sham-operation (Sham) and 
incubated for 4 h with (grey bars) or without LPS (white bars). Cellular supernatants were collected and 
TNF-α was detected by ELISA. Hemorrhage caused a significant reduction of LPS-induced TNF-α 
synthesis. Data represent mean ± SD of 4 independent experiments with pooled macrophages of 2 mice 
/group. * Means statistical significant difference to shock vs. sham LPS for TNF-α synthesis in Mann-
Whitney-U-Test.   *, p< 0.05. 
 
3.1.3.2.3 LPS-induced IκBα signaling after hemorrhage 
The Nuclear Factor (NF)κB is considered to be the predominant transcription factor that 
regulates TNF-α response in most cells. NFκB is under control of its inhibitor IκB and is 
only transferred to the nucleus upon phosphorylation and ubiquitin-dependent 
degradation of IκB (Figure 3). Therefore, the activation of the NFκB pathway was 
indirectly analyzed by determination of the phosphorylated form of the cytoplasmic 
inhibitor of NFκB, the IκBα protein. P-IκBα was enhanced upon LPS stimulation in both 
sham and shock mice, however, the phosphorylation were less intense in macrophages 
from mice after hemorrhagic shock than after sham operation. Nonphosphorylated IκBα 
signal was found to be more intense after hemorrhage as expected. Thus, in peritoneal 
macrophages harvested 20 h after hemorrhage the reduced TNF-α production after LPS 
stimulation was accompanied by a decreased IκBα phosphorylation while the 
unphosphorylated form of IκBα was enhanced after hemorrhagic shock (Figure 24).  
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Figure 24. LPS-induced IκBα phosphorylation in peritoneal macrophages after hemorrhage. 
Peritoneal macrophages (pooled cells from 2-3 mice/group) were harvested 20 h after hemorrhage (Shock) 
or sham-operation (Sham) and incubated for 45 min with or without LPS (Med). Cytoplasmic proteins 
were extracted and both phosphorylated as well as nonphosphorylated IκBα was analyzed by Western 
blotting. The blot shown is representative of a minimum of three independent experiments.  
 
3.1.3.2.4 LPS-induced ERK1/2 and P38 signaling after hemorrhage 
Various cytokines including TNF-α are regulated by cytoplasmic kinases belonging to 
the MAPK family. Both the P38MAPK and ERK1/2 were analyzed in peritoneal 
macrophages isolated 20 h post hemorrhagic shock with and without LPS-stimulation. In 
accordance with the response of IκBα phosphorylation, ERK1/2 activation was also 
found to be less in peritoneal macrophages isolated 20 h after hemorrhagic shock when 
compared with the response in peritoneal cells harvested from sham-operated animals. In 
contrast, the P38MAPK was found to be obviously induced after shock in peritoneal 
macrophages even without additional LPS-stimulation. After LPS-application in vitro the 
phosphorylation of P38MAPK was much more intense than in correspondingly treated 
cells from sham-operated mice (Figure 25). 
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Figure 25. LPS-induced P38 and ERK1/2 signaling in peritoneal macrophages after hemorrhage. 
Peritoneal macrophages (pooled cells from 2-3 mice/group) were harvested 20 h after hemorrhage (Shock) 
or sham-operation (Sham) and incubated for 45 min with or without LPS. Cytoplasmic proteins were 
extracted; P-P38 and P-ERK1/2 were analyzed by Western blotting. Blots were probed sequentially with 
anti-P38 and anti-ERK1/2 antibodies to determine the total amount of the respective kinase loaded. The 
blot shown is representative of a minimum of three independent experiments.  
 
3.1.3.2.5 GM-CSF preincubation enhanced the TNF-α production after hemorrhage 
When GM-CSF is applied in vitro on peritoneal macrophages harvested from mice 20 h 
after hemorrhagic shock, GM-CSF slightly, but significantly enhances the LPS-induced 
TNF-α synthesis (Figure 26). The stimulatory effect of GM-CSF in macrophages from 
shocked animals was less obvious and only 1.6 fold in comparison to a 2.3 fold increase 
in macrophages from sham-operated animals. However, the treatment with GM-CSF in 
vitro was sufficient to activate TNF-α production to the level of peritoneal cells from 
sham-operated mice without GM-CSF incubation, which can be assumed as normal 
TNF-α-producing capacity (Shock+LPS+GM-CSF vs. Sham+LPS; p=0.234). 
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3.1.3.2.6 IκBα phosphorylation in GM-CSF primed
The modest increase of TNF-α production of peritone
animals after GM-CSF incubation was accompan
phosphorylated IκBα. However, similar as the TNF-α
also much more primed by GM-CSF in peritoneal cel
the unphosphorylated form of IκBα was decreased af
(Figure 27).  
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Figure 27. IκBα phosphorylation in GM-CSF primed macrop
Peritoneal macrophages (pooled cells from 2-3 mice/group) were
or sham-operation (Sham) and incubated first for 6 h with GM-C
(1 ng/ml) along with their respective controls. Cytoplasmic p
analyzed by Western blotting. The blot shown is representati
experiments.  
 
 Figure 26. Elevated TNF-α production 
after GM-CSF preincubation after 
hemorrhage.  
Peritoneal macrophages were harvested 20 
h after hemorrhage (Shock) or sham-
operation (Sham) and incubated first for 6 
h with GM-CSF (10 ng/ml) and then 4 h 
with LPS (1 ng/ml) along with their 
respective controls. TNF-α production is 
expressed as percentage of LPS-induced 
TNF-α-production of the sham-operated 
animals of each set of experiments. Data 
represent mean ± SEM of 4 independent
experiments with pooled macrophages of 2 
mice /group. * means statistical significant 
different to sham-operated mice after LPS-
stimulation with a p-value< 0.05 in Mann-
Whitney-U-Test; ≠ indicates statistical 
difference to incubation without GM-CSF 
(Wilcoxon-Test for unpaired samples).  macrophages after hemorrhage  
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3.1.3.2.7 P-ERK1/2 and P38 phosphorylation in GM-CSF primed macrophages 
after hemorrhagic shock  
In contrast to the modest effect of GM-CSF treatment in terms of TNF-α production, the 
signaling molecules ERK1/2 and P38 were obviously enhanced by GM-CSF 
preincubation in both macrophages from sham-operated and shocked mice. GM-CSF 
given in vitro activated both the P38MAPK and ERK1/2 phosphorylation in peritoneal 
macrophages after hemorrhage. The stimulation of ERK1/2 by GM-CSF in cells from 
hemorrhagic animals was similar to the level of ERK1/2 from sham-operated mice, 
which may be assumed as the “normal” level. The upregulation of P38MAPK after 
hemorrhagic shock was found to be even more elevated after GM-CSF treatment (Figure 
28). 
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Figure 28. ERK1/2 and P38 phosphorylation after hemorrhage and GM-CSF incubation  
Peritoneal macrophages (pooled cells from 2-3 mice/group) were harvested 20 h after hemorrhage (Shock) 
or sham-operation (Sham) and incubated first for 6 h with GM-CSF (10 ng/ml) and then 45 min with LPS 
(1 ng/ml) along with their respective controls. Cytoplasmic proteins were extracted and P-ERK1/2 and P-
P38 were analyzed by Western blotting using specific antibodies for phosphorylated ERK1/2 and 
P38MAPK and the respective control antibody detecting the total amount of each kinase. The blot shown is 
representative of a minimum of three independent experiments.  
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3.1.4 Immunomodulation by GM-CSF during polymicrobial sepsis 
GM-CSF is known to enhance monocytes’ and macrophages’ effector functions after 
shock as well as during sepsis [87, 88, 94, 95]. GM-CSF restores the capacity of splenic 
and peritoneal macrophages for TNF-α secretion in response to LPS. With the results 
shown above, GM-CSF partly but not completely, could restore the suppressed immune 
functions of murine peritoneal macrophages after hemorrhagic shock. Like hemorrhagic 
shock, sepsis leads to the development of immunosuppression that is associated with the 
impaired capacity of antigen presenting cells (APC) in the spleen to respond to bacterial 
stimuli. To test whether GM-CSF might reverse the suppressive state of APC in the 
spleen during sepsis, the secretion of pro-inflammatory cytokines by splenic 
macrophages and dendritic cells was analyzed in the presence of GM-CSF. 
 
3.1.4.1 TNF-α secretion by splenic macrophages and dendritic cells  
The capacity of GM-CSF to modulate the TNF-α production by LPS-induced antigen 
presenting cells such as splenic macrophages and dendritic cells was investigated during 
polymicrobial sepsis. Total spleen cells (TSC) were prepared after 24 h sham or CLP 
operation since former experiments had revealed a significant TNF-α secretion in the 
supernatant at this time point. TSC were cultured with or without 10 ng/ml LPS each in 
the presence or absence of 20 ng/ml GM-CSF. Unstimulated cells served as the control 
(Med). The cells were stained for macrophages and dendritic cells using F4/80+ and 
CD11c+ surface markers, respectively. Intracellular expression of TNF-α was determined 
in F4/80+ macrophages and CD11chi dendritic cells by means of FACS.  
Concerning macrophages, the production of TNF-α was low in the absence of any 
stimulation (Med) from both control and septic mice (Figure 29A). Stimulation with 
GM-CSF alone did not enhance the level of TNF-α and was found to be similar to the 
level of unstimulated cells after sham and CLP operation. Upon LPS stimulation, 25% of 
splenic macrophages after sham operation produced TNF-α.  Splenic macrophages after 
CLP also produced TNF-α but to a lesser extent (1.6-fold; Figure 29A, CLP vs. sham, 
LPS) than macrophages from control animals upon LPS-stimulation. The treatment with 
GM-CSF enhanced the capacity of LPS-induced macrophages to synthesize TNF-α, both 
after CLP and sham operation (1.6-fold and 1.3-fold, respectively; Figure 29A). The 
presence of GM-CSF during LPS stimulation increased the percentage of TNF-α-
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producing macrophages from septic mice up to levels observed for LPS-stimulated 
macrophages from healthy controls. 
Dendritic cells from both control and septic mice, like macrophages, produced low levels 
of TNF-α in the absence of any stimulation (Med, Figure 29B). GM-CSF stimulation 
alone did not enhance the level of TNF-α and was found to be similar to the level of 
unstimulated cells after sham and CLP operation. Twenty-four hours post CLP; dendritic 
cells did not show any response to LPS stimulation and showed a strong reduction in 
TNF-α producing capacity (70%; Figure 29B, CLP vs. sham, LPS). GM-CSF treatment 
of LPS-induced dendritic cells from mice of both the groups increased the TNF-α 
secretion (Figure 29B) to a similar degree as for the macrophages (1.5-fold of DC vs. 
1.6-fold of macrophages, Figure 29A vs. B, GM-CSF + LPS). In spite of an increase in 
TNF-α production after GM-CSF treatment by dendritic cells, the percentage of TNF-α 
producing DC from septic mice did not reach the levels found for LPS-stimulated DC 
from sham mice (71% suppression, Figure 29B, CLP vs. sham, GM-CSF + LPS). 
Thus, sepsis-associated reduction in LPS-induced TNF-α production is more pronounced 
in dendritic cells than in macrophages. GM-CSF enhanced the LPS-induced TNF-α 
synthesis of macrophages up to the levels from LPS-treated macrophages from sham 
mice. However, GM-CSF did not compensate the strong suppression of dendritic cells 
from septic mice.  
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Figure 29. Enhanced TNF-α production after GM-CSF treatment. 
Total spleen cells were pooled (n=3-4 per group) 24 h post sham or CLP operation and stimulated with or 
without 10 ng/ml LPS each in the presence or absence of 20 ng/ml GM-CSF for 1 h. Unstimulated cells 
served as the control (Med). After 4 h further incubation with monensin, spleen cells were stained for 
F4/80 (A) and CD11c (B) surface markers and intracellular TNF-α (common for Figure A and B). F4/80 
and CD11chi cells were gated. Quadrant lines were set according to the isotype control antibody, staining 
less than 1-2% of the cells. Numbers indicate percentage of TNF-α-positive cells. The FACS data are 
representative of 3 independent experiments.  
 
3.1.4.2 IL-12 secretion by splenic dendritic cells  
Reduction of IL-12 production by dendritic cells has been documented after 
polymicrobial sepsis [80]. In this study, we investigated the role of GM-CSF for the 
modulation of LPS-induced DC to enhance IL-12p40 production during sepsis. Twenty-
four hours after CLP or sham operation, total spleen cells were prepared and cultured 
with or without 5 µg/ml CpG each in the presence or absence of 20 ng/ml GM-CSF. 
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Unstimulated cells served as the control (Med). Intracellular expression of IL-12p40 was 
determined in CD11chi dendritic cells by means of FACS. A low percentage of DC from 
sham and CLP mice produced IL-12p40 in the absence of any stimulation (Figure 30). 
GM-CSF stimulation alone showed a similar percentage of IL-12p40 producing dendritic 
cells. More than 50% of DC from sham mice but only 12% of DC from septic produced 
IL-12p40 upon stimulation with CpG (Figure 30, CLP vs. sham, CpG). GM-CSF 
treatment slightly enhanced the IL-12p40 production from CpG-stimulated cells in case 
of sham operated animals (1.3-fold; Figure 30, Sham, GM-CSF + CpG vs. CpG only) 
while the effect of GM-CSF was much more pronounced in DC from septic mice (1.9-
fold, Figure 30, CLP, GM-CSF + CpG vs. CpG only). However, the presence of GM-
CSF during CpG stimulation did not restore the capacity of DC to produce IL-12p40 
similar to DC from sham mice and thus did not compensate the strong suppression of 
dendritic cells in septic animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dendritic cells 
Figure 30. Enhanced IL-12p40 production after GM-CSF treatment. 
Total spleen cells were pooled (n=3-4 per group) 24 h post sham or CLP operation and stimulated with or 
without 5 µg/ml CpG each in the presence or absence of 20 ng/ml GM-CSF for 18 h. Unstimulated cells 
served as the control (Med). After 4 h further incubation with monensin, spleen cells were stained for 
CD11c surface marker and intracellular IL-12p40. CD11chi cells were gated. Quadrant lines were set 
according to the isotype control antibody, staining less than 1-2% of the cells. Numbers indicate percentage 
of TNF-α-positive cells. The FACS data are representative of 3 independent experiments.  
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3.1.4.3 Effect of GM-CSF on CD86 and CD40 on splenic DC 
To test whether GM-CSF affects the expression of co-stimulatory molecules on splenic 
dendritic cells, the expression of CD86 (Figure 31A) and CD40 (Figure 31B) on splenic 
CD11chi DC was determined 24 h post CLP and sham operation. GM-CSF alone after 
sham operation enhanced the expression of CD86 but not of CD40 on dendritic cells. 
Upon LPS stimulation, the expression of both CD86 (5-fold) and CD40 (4-fold), on DC 
from sham mice was increased. DC from septic mice only weakly increased the 
expression of these co-stimulatory molecules upon stimulations with LPS. GM-CSF 
alone increased the expression of CD86 but not of CD40 on DC from septic animals. The 
presence of GM-CSF during LPS-stimulation significantly increased the expression of 
CD86 on DC from septic mice (in comparison to stimulation with LPS alone). GM-CSF 
did not change the LPS-mediated expression of CD86 on DC from sham mice or of 
CD40 on DC from both the groups. Thus, GM-CSF could restore at least in part the 
decreased upregulation of CD86 on DC from septic mice upon stimulation with LPS.  
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Figure 31. Maturation of splenic DC during sepsis. 
Total spleen cells were pooled (n=3-4 per group) 24 h post CLP and sham operation and stimulated with or 
without 10 ng/ml LPS each in the presence or absence of 20 ng/ml GM-CSF for 18 h. The cells were 
stained for CD11c, CD86, CD40 and isotype controls. CD11chi cells (DC) were used for gating. The ratio 
of MFI values of CD86 (A) and CD40 (B) upon stimulation versus medium control (set as 1) was 
calculated from DC from septic (black bars) and sham (open bars) mice. Data show mean ± SD of three to 
four independent experiments. * indicates significant difference (p<0.05) between LPS and GM-CSF+LPS 
groups. 
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3.2 GM-CSF as a growth regulator 
 
GM-CSF is one of the members of colony stimulating factors that are required for the 
survival, proliferation, and differentiation of hematopoietic progenitor cells of myeloid 
and erythroid origin. In developing bone marrow, GM-CSF stimulates immature myelo-
monocytic progenitor cells to proliferate and differentiate. In addition to its function as a 
growth factor, GM-CSF primes the mature cells from these lineages, so when they 
encounter an invading pathogen, they are capable of initiating a full defense reaction 
[151]. Therefore, the effect of GM-CSF on the development of bone marrow progenitors 
of dendritic cells was further explained. It has been shown by our research group that DC 
from the spleen undergo strong modulation in terms of their phenotype and cytokine 
production patterns. There was a DC loss during polymicrobial sepsis and the remaining 
DC showed an aberration in the cytokine secretion that favored the development of Th2 
cells [80]. In order to understand, whether sepsis additionally modulates the progenitor 
cells of DC, the effect of GM-CSF on the development of bone marrow progenitors, 
especially for the dendritic cells was studied. The effect during polymicrobial sepsis in 
terms of modulation of progenitor cells of DC and DC differentiation, expression of co-
stimulatory molecules, cytokine secretion and in vitro and in vivo T cell activation was 
investigated. 
 
3.2.1 BMC loss during polymicrobial sepsis 
To understand the effects of sepsis on total bone marrow cell count, these cells were 
analyzed 24 h after CLP or sham operation. The BMC were prepared and enumerated. A 
reduced number of BMC was found in septic mice in comparison to sham mice, 
indicating a clear and significant loss of 40% of BMC (Figure 32).  
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Figure 32. BMC count during sepsis. 
Twenty-four hours post CLP or sham 
operation, total BMC were pooled (n=2-3 
per group) from sham (open squares) and 
CLP (filled triangles) mice and counted.
Data show absolute counts ± mean of BMC
of all the individual experiments. n: 
Number of total experiments as indicated. 
Asterisks indicate statistically significant 
difference between CLP and sham group.
***, P < 0.0005. 
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3.2.2 Cell death during polymicrobial sepsis 
Increased cell death could be one of the possible explanations of cell loss in the bone 
marrow after CLP operation. To address this parameter, apoptosis was checked in order 
to know whether there is enhanced cell death in the bone marrow during sepsis. Sham 
and septic BMC were stained for Annexin-V in combination with 7-AAD, a vital dye, to 
simultaneously distinguish live, early apoptotic and late apoptotic/dead cells. In early 
apoptotic cells, the membrane phospholipids phosphatidylserine (PS) is translocated and 
thereby exposed to the external cellular environment. Annexin V has a high affinity for 
PS and binds to cells with exposed PS. Annexin V staining precedes the loss of 
membrane integrity, which accompanies the latest stages of cell death resulting from 
either apoptotic or necrotic processes. Therefore, staining with Annexin V was used in 
conjunction with a vital dye, such as 7-Amino-actinomycin D (7-AAD) to allow the 
discrimination of early apoptotic cells. Viable cells were Annexin V and 7-AAD 
negative. Cells that were in early apoptosis were Annexin V positive and 7-AAD 
negative (Figure 33A, R1 and B). Early induction of apoptosis was 3.6-fold more in 
septic BMC as compared to BMC from sham mice. Cells that are in late apoptosis/cell 
death were positive for both Annexin V and 7-AAD (Figure 33A, R2 and B) and were 
2.2-fold more after cecal ligation and puncture. Total apoptotic and dead cells were the 
combination of R1+R2 region cells and showed overall 2.5 fold more dead cells after 24 
h sepsis (Figure 33A, R1+R2 and B). 
Additionally, Caspase-3, another apoptotic cells marker, was checked to determine the 
percentage of dead cells. Caspases are the main effectors of apoptosis or programmed 
cell death (PCD) and their activation leads to characteristic morphological changes of the 
cell consequently leading to its death. Initiator caspases are the first to be activated which 
cleave and activate the effector caspases e.g. caspase-3, that gives the signal for cell 
death. Caspase-3 staining of BMC further strengthened the data from Annexin-V and 7-
AAD staining and also showed an increase of 2.5-fold in apoptotic cells 24 h post CLP as 
compared to BMC of sham mice (Figure 33C, R1 and D).  
However, the percentage of dead cells as such was low in both sham and septic BMC not 
reaching more than 6%, albeit the number of dead cells was higher in BMC isolated from 
septic mice as compared to BMC from sham mice, shown by both Annexin-7-AAD 
(Figure 33A and B) and caspase-3 staining (Figure 33C and D). 
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Figure 33. Cell death in the bone marrow during polymicrobial sepsis. 
Twenty-four hours post CLP or sham operation, total BMC were pooled (n=2-3 per group) and stained for 
Annexin-V in combination with 7-AAD or for Caspase-3. (A) Representative dot plot showing Annexin-V 
and 7-AAD staining with individual gating for Annexin-V+ cells (R1), Annexin-V+ and 7-AAD+ cells (R2) 
and 7-AAD+ cells (R3). (B) Data showing mean ± SD of three independent experiments showing 3 
different populations from region R1, R2 and R1 + R2 as gated in part-A from sham and septic BMC. The 
ratios were calculated as fold increase of percentage values of BMC from septic (black bars) versus sham 
(open bars) mice to compensate for variations between different experiments. (C) Representative dot plot 
for Caspase-3 staining against SSC-Height with Caspase-3 gated as R1. (D) Caspase-3 staining from 3-4 
individual mice per group. Values are shown as percentage of Caspase-3+ cells from sham (open bars) and 
septic (black bars) BMC. Asterisks indicate statistically significant difference between CLP and sham 
group. ***, P < 0.0005. 
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3.2.3 Release of myeloid cells from bone marrow into the blood 
Enhanced release of myeloid cells from the bone marrow could be another explanation 
for the reduced numbers of BMC during sepsis. To investigate this possibility, cell 
number and cellular composition of whole blood were analyzed. 
 
3.2.3.1 Increased leukocyte count during polymicrobial sepsis 
First, the total leukocyte count in the blood was analyzed. Blood was collected and 
stained for the leukocyte marker, CD45. Blood isolated from septic mice clearly showed 
a significant increase in total leukocyte count (5.3-fold) as compared to sham mice 
(Figure 34A), indicating the enhanced release of these cells from bone marrow into the 
blood. 
 
 
 
 
 
 
 
 
 
 
Figure 34. Leukocyte count in the blood 24 h post CLP. 
Blood was collected 24 h post CLP or sham operation and 50 µl of blood was used for the staining of 
CD45 expression on blood cells in TruCount Tubes as described in Material and Methods (Section 
2.3.7.2). The cells were gated for CD45 against FSC channel (R1). Leukocyte count was calculated per 
1000 µl of blood. The dot plots are representative of two independent experiments.  
 
3.2.3.2 Elevated dendritic cell count during polymicrobial sepsis 
Next, the blood was analyzed for the myeloid cell composition after 24 h of sham and 
CLP operation. Blood was stained with CD11c, dendritic cell surface marker in 
combination with MHC class II surface marker, a marker for the maturation status of the 
dendritic cells. Sepsis led to an increase of 38.5 ± 2.5% more dendritic cells in the blood 
as compared to DC from sham blood (Figure 35B vs. A, R1). Although the total 
dendritic cell (CD11c+, Figure 35A, R1) number was found to be more in septic blood, 
the differentiated dendritic cells (CD11c+MHC II+) were less by 34 ± 8% (Figure 35D 
vs. C, R2) in the same septic blood. Thus, during sepsis, the number of immature DC but 
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not the differentiated DC with an overall total CD11c+ cell number was increased in the 
blood.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Dendritic cell count in the blood during sepsis. 
Blood was collected 24 h post CLP or sham operation and stained for CD11c in combination with MHC 
class II. CD11c+ cells were used for the gating. (A and B) Dot plots from the gated DC in the region R1 
from blood cells of sham and septic mice. (C and D) MHC class II expression on gated DC is shown and 
CD11c+MHC+ cells are shown in region R2. Quadrant lines were set where isotype controls showed less 
than 2% false-positive cells. Data show representative dot plots of two independent experiments. 
 
3.2.3.3 Increased granulocyte and monocyte release during polymicrobial sepsis 
Further, the blood was analyzed for other myeloid cells such as granulocytes and 
monocytes after 24 h of sham and CLP operation. Blood staining was performed with 
CD11c in combination with Gr1 and CD11b markers. Granulocytes were analyzed using 
granulocyte antigen, Gr1 and monocytes were studied by taking the cell population 
devoid of dendritic cells and granulocytes (CD11c-Gr-) and then gating this negative 
population for CD11b in a combination with Gr1, a marker to characterize monocytes 
and macrophages (CD11b+Gr1+). An increase in granulocyte (58.6%, Figure 36B vs. A, 
R1) and monocyte (33.33%, Figure 36D vs. C, R2) percentage was found in the blood 
of septic mice compared to the same from the blood of sham mice. This clearly stated the 
release of granulocytes and monocytes from bone marrow to blood. 
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Figure 36. Granulocyte and monocyte count in the blood during sepsis. 
Blood was collected 24 h post CLP or sham operation and stained for CD11c in combination with Gr1and 
CD11b and MHC class II. (A) Granulocytes (Gr1+) cells were gated against FSC channel. (B) The cells 
other than the granulocytes (CD11c-Gr1-) were gated and used for analyzing monocyte population using 
CD11b+ against Gr1+ cells. Data show representative dot plots of two independent experiments. 
 
3.2.4 Cell proliferation and DC composition during sepsis 
3.2.4.1 Enhanced bone marrow cell proliferation during polymicrobial sepsis 
To further understand the mechanisms leading to the reduced BMC number during 
sepsis, the proliferation capacity of BMC was investigated. Therefore, 24 h post CLP or 
sham operation, bone marrow cells were prepared. An equal number of CFSE-labeled or 
unlabeled BMC were cultured and the proliferation of labeled cells was analyzed by 
means of FACS on d 3 and unlabeled cells were counted for proliferation on d 3 and 7. 
After every cell division, CFSE labeling was distributed equally between the daughter 
cells distinguishing consequently, each successive generation by decreased CFSE 
labeling of the cells. Twenty-four hours after CLP, percentage of non-dividing-CFSE-
labeled cells was decreased by 54.2% (Figure 37A, CLP vs. sham, M2 population) 
indicating that there was an increased proliferation (Figure 37A, CLP) of these cells 
during sepsis. The increase in BMC proliferation after sepsis was further confirmed by 
the counting of the cells from d 3 and d 7 cultures (Figure 37B). During culture, BMC 
from septic mice strongly proliferated and generated up to 2.0-fold and 2.3- fold more 
cells after d 3 and d 7 respectively, than BMC from sham mice. The increased 
proliferation from septic cells was more prominent on d 7 as compared to d 3. Thus, 
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sepsis resulted into a strong proliferation of bone marrow cells which started as early as d 
3 of culture and continued further through d 7. 
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Figure 37. BMC proliferation during polymicrobial sepsis. 
Twenty four hours post CLP, total BMC were pooled (n=2-3 per group). 2x106, CFSE-labeled (A) or 
unlabeled (B) BMC from sham and CLP mice were cultured in Petri-dishes. (A) Proliferation of sham and 
septic CFSE-labeled CD11c- BMC after d 3 culture.  CFSE positive cells were gated on the basis of 
dividing (M1) and non dividing (M2) populations. Dot plot shown are representative of two independent 
experiments. (B) Cell count of unlabeled BMC from sham (open squares) and septic mice (filled triangles) 
on d 0, 3 and 7. Data show absolute counts ± mean of BMC/Petri-dish of all the individual experiments. n: 
Number of total experiments as indicated. Asterisks indicate statistically significant difference between 
CLP and sham group. **, P < 0.005; ***, P < 0.0005. 
 
3.2.4.2 DC population during polymicrobial sepsis 
Next, the possible explanation for the enhanced proliferation of bone marrow cells after 
sepsis was evaluated. BMC were analyzed for the content of dendritic cells and its 
progenitors to know whether these show any change which could give rise to increased 
proliferation during polymicrobial sepsis. Twenty-four hours after sham or CLP 
operation, BMC were prepared and studied for differentiated DC (CD11c+MHC class II+) 
and DC progenitor cells (CD11c+MHC class II-) by means of FACS. There was a 
consistent but slight elevation in the DC number from septic mice as compared to DC 
from sham mice (Figure 38A). However, BMC from septic mice contained a 1.6 to 2.6-
fold higher number of differentiated DC (Cd11c+MHC class II+, Figure 38B, IA+) but 
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CD11c+MHC class II- progenitor cell count remained unchanged (Figure 38B, IA-). DC 
number did not change after CLP operation during the culture over d 7 and was akin to 
the sham DC proliferation tested on d 3 and then d 7 (Figure 38C).  
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Figure 38. DC proliferation during polymicrobial sepsis. 
Twenty-four hours after sham or CLP, total BMC were pooled (n=2-3 per group) and stained for CD11c in 
combination with MHC class II surface marker. CD11c+ cells were gated and MHC II expression was 
analyzed on these cells. (A) The total number of DC per mouse after sham (open bars) and CLP operation 
(black bars) were calculated. BMDC number per mouse was calculated as % gated CD11c+ cells x total 
number of cells per bone marrow/10. (B) The total numbers of CD11c+MHCII- (IA-) and CD11c+MHCII+ 
(IA+) per mouse of sham (open bars) and septic mice (black bars) were calculated. The calculations were 
done as follows: CD11c+MHCII- (IA-) = number of BMDC per mouse x MHCII- DC$/100; 
CD11c+MHCII+ (IA+) = number of BMDC per mouse - CD11c+MHCII- (IA-). (C) Proliferation of d 3 and 
d 7 CD11c+ cells from sham (open bars) and septic (black bars) BMC was compared to the proliferation on 
d 0 to get the effective proliferation of dendritic cells. Data show mean ± SEM of the pooled number of 
experiments as indicated. Asterisks indicate statistically significant difference between CLP and sham 
group. ***, P < 0.0005.  $was calculated by subtracting the percentage of gated CD11c+MHCII+ cells from 
100. 
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3.2.5 Cytokine secretion pattern during polymicrobial sepsis 
3.2.5.1 Aberrant cytokine secretion pattern of BMDC during sepsis 
A number of functional defects in dendritic cells during sepsis have been characterized. 
These defects include dysregulated cytokine production, changed expression of 
important cell surface antigens and reduced T cell activation capacity. Therefore, the 
capacity of BMDC to produce various pivotal cytokines such as IL-10 (Figure 39A), IL-
12p70 (Figure 39B), IL-12p40 (Figure 39C) and TNF-α  (Figure 39D) which are the 
key mediators for inflammatory response were analyzed. BMDC on d 7, were stimulated 
with or without LPS, LPS+CD40L, CpG oligonucleotides, PGN or bacteria for 18 h and 
the supernatants were analyzed for the above stated cytokines. Unstimulated BMDC 
served as control (Med) and from both sham and septic mice produced very low levels of 
IL-10, IL-12 (both IL-12p70 and IL-12p40) and TNF-α. BMDC from septic mice 
secreted more IL-10 but not IL-12p70 upon LPS stimulation than BMDC from sham 
mice. However, both IL-10 and IL-12p70 production were enhanced by stimulating the 
cells with CD40L along with LPS. While IL-12p70 production after sepsis was 
comparable, IL-12p40 showed a decreased secretion in response to LPS. The levels of 
IL-10 as well as IL-12p70 from septic BMDC were elevated upon CpG or bacterial 
stimulations when compared with BMDC from sham treated mice. However, the 
increased levels of IL-12p70 production was not consistent in all the experiments and 
sometimes a slight increase or no change was observed for septic BMDC upon CpG  or 
bacterial stimulation when compared to sham BMDC. Upon LPS treatment, septic 
BMDC produced reduced levels of IL-12p40 in response to CpG and bacterial 
stimulations. Low levels of IL-10 and IL-12 were released in PGN-stimulated BMDC 
and the levels were comparable after sham or CLP operation. TNF-α secretion was 
unchanged from septic BMDC regardless of any stimulation as compared to sham 
BMDC. Taken together, during sepsis, BMDC develop an aberrant cytokine secretion 
pattern in response to bacterial stimuli associated with a predominance of IL-10. 
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Figure 39.  Cytokine pattern of BMDC in response to bacterial components. 
BMC after 24 h CLP or sham operation, were cultured for d 7 to generate BMDC and then stimulated in 
the absence or presence of 100 ng/ml LPS alone or in combination with 2.5 µg/ml CD40L, or with 5 µg/ml 
CpG, 3 µg/ml PGN or bacterial preparation for 18 h. Supernatants of BMDC from septic mice (black bars) 
and from sham mice (open bars) were analyzed for IL-10 (A), IL-12p70 (B), IL-12p40 (C) and TNF-α (D). 
Data show mean ± SD of triplicate cultures and are representative of a minimum of four experiments. 
Asterisks indicate significant differences between cultures of sham and CLP groups. *, P < 0.05; ***, P < 
0.0005. n.d., not determined. 
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3.2.5.1.1 Unchanged CD40, CD86 and MHC class II expression of BMDC during 
polymicrobial sepsis 
Next, the effect of sepsis on the maturation status of BMDC in response to different 
bacterial components was investigated. Therefore, CD40, CD86 and MHC class II 
expression on CD11c BMDC was determined after sham and CLP operation. The non-
stimulated-BMDC from both sham and septic mice showed low expression of surface 
molecules and the expression of these CD40, CD86 and MHC class II markers was 
strongly upregulated in response to LPS, CpG, PGN and bacteria as expected. However, 
neither upregulation nor down regulation of any of the surface markers was seen after 24 
h sepsis clearly indicating no effect of sepsis on the expression of these surface markers 
(Figure 40). 
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Figure 40. Maturation of BMDC during polymicrobial sepsis. 
BMC after 24 h CLP or sham operation were cultured for 7 d to generate BMDC and then stimulated in the 
absence or presence of LPS, CpG, PGN or bacterial preparation for 18 h. Non-adherent cells were pooled 
and stained for CD11c+ in combination with MHC class II, CD40 and CD86. CD11c cells were used for 
the gating and MHC class II, CD86 and CD40 were then analyzed on CD11c+ gated cells of sham (open 
bars) and septic mice (black bars). MFI-fold-values of the indicated surface markers for all the given 
stimuli were normalized on sham medium taking that as 1. Data show mean ± SD of three to four 
independent experiments. 
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3.2.5.2 Reduced cytokine secretion pattern of BMC during sepsis 
In order to test whether any cytokine that would promote the enhanced IL-10 release is 
present in the BMC cultures, the cytokine secretion of BMC prepared 24 h after CLP or 
sham operation was investigated. The cytokine pattern from BMC was analyzed for IL-
10 (Figure 41A), IL-12 (Figure 41B) and TNF-α release (Figure 41C). BMC were 
prepared 24 h post CLP and sham operation and cultured with or without LPS, CpG, 
PGN or bacteria. In the absence of any stimulation (Med), neither IL-10 nor IL-12p70 
was synthesized by BMC from both sham and septic mice, though very low level of 
TNF-α was secreted by BMC from both the groups. BMC from sham mice responded 
strongly to CpG as compared to other stimulations i.e. LPS, PGN and bacteria for the 
production of IL-10 and IL-12. However, during sepsis, BMC showed a drastic decline 
in the production of IL-10 and IL-12 upon stimulation with any bacterial stimuli, but the 
reduction was more prominent in CpG-stimulated BMC. There was a considerably 
higher secretion of TNF-α in response to all the given stimuli from both sham and septic 
BMC, but when compared between sham and septic BMC, TNF-α production was 
significantly low from septic BMC. Thus, IL-10, IL-12p70 cytokine levels were 
undetectable and TNF-α secretion was in very low amounts from both sham and septic 
BMC under nonstimulated conditions. There was a drastic decline in the production of 
all the stated cytokines upon stimulation with any bacterial component e.g. LPS, CpG, 
PGN or bacterial preparation. 
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Figure 41. Cytokine pattern of BMC in response to bacterial components. 
BMC after 24 h CLP or sham operation were cultured in the absence or presence of LPS or with CpG, 
PGN or bacterial preparation for 18 h. Supernatants of DC from sham (black bars) and septic mice (open 
bars) were analyzed for IL-10 (A), IL-12p70 (B) and TNF-α  (C). Data show mean ± SD of triplicate 
cultures and are representative of a minimum of four experiments. Asterisks indicate significant 
differences between cultures of sham and CLP groups. *, P < 0.05; ***, P < 0.0005.  
 
3.2.6 T cell activation during polymicrobial sepsis 
3.2.6.1 In vitro T cell-stimulatory capacity of BMDC during sepsis  
To investigate the capacity of BMDC to induce T cell activation, CpG-induced T cell 
proliferation and cytokine production in sham and septic mice was examined. Titrated 
numbers of purified BMDC from sham and septic mice, in the presence or absence of 
CpG (5 µg/ml) were cocultured with allogenic CFSE-labeled T cells. After d 3, the non-
adherent cells were checked for proliferating T cells by gating CFSE-positive CD4+ 
viable and proliferating T cells using FACS (Figure 42A). BMDC from both sham and 
septic mice showed similar T cell proliferation capacity in the absence (Med. Figure 42B 
and C vs. D) or presence of stimulation (CpG, Figure 42B and E vs. F). The 
proliferation capacity was found to be same with all the titrated numbers of BMDC 
(Figure 42G). However, an enhanced T cell proliferation in response to CpG-stimulated 
BMDC as compared to non-stimulated BMDC (Figure 42B and C, D vs. E, F and G) 
was found for both the groups of mice.  
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IFN-γ, a pivotal cytokine produced by T cells during the proliferation indicating the 
polarization of Th cells towards Th1, was analyzed in BMDC/T cell coculture 
supernatants after d 3. Non-stimulated BMDC from both sham and CLP operated mice 
induced the T cells to secrete low levels of IFN-γ and septic BMDC induced the T cells 
to release even lower amounts of IFN-γ when compared with BMDC from sham mice. 
IFN-γ synthesis was increased many-fold from the T cells cocultured with BMDC upon 
CpG stimulation (Figure 42H). T cells cultured with BMDC from septic mice inspite of 
having the same proliferation as that of sham BMDC/T cell cocultures, produced up to 
two-fold less IFN-γ upon CpG stimulation (Figure 42H). Thus, BMDC from septic mice 
showed same T cell proliferative capacity but were less effective in inducing T cell 
derived IFN-γ synthesis than BMDC from sham mice. 
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Figure 42. In vitro T cell proliferation and IFN-γ synthesis during sepsis. 
BMC after 24 h CLP or sham operation, were cultured for d 7 to generate BMDC. Titrated numbers of 
BMDC were cultured in the absence and presence of CpG in 96-well plates for 18 h and then CFSE-
labeled, allogenic T cells were added to it. After d 3, non-adherent cells were analyzed for proliferation (A-
G) as described in Materials and Methods (Section 2.3.7.3) and the supernatants were tested for IFN-γ by 
ELISA (42H). (A) Histogram showing M1 population along with the mother population of proliferating T 
cells. (B) Representative graph from one of the BMDC titrated cells with or without CpG stimulation. (C-
F) Histograms only with M1 population of proliferating T cells with or without CpG stimulation. (G) 
Graphical representation for all the titrations of BMDC/T cell cocultures in the absence or presence of 
CpG. (H) IFN-γ ELISA from the supernatants of BMDC/T cell cocultures collected after d 3.  Data show 
mean ± SEM of triplicate cultures of BMDC with medium (open squares), and after CpG stimulation (open 
circles) from sham mice and with medium (solid squares), and after CpG stimulation (solid circles) from 
septic mice and are representative of three experiments. Asterisks indicate significant differences between 
cultures of sham and CLP groups. *, P < 0.05; ***, P < 0.0005.  
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3.2.6.1.1  Increased IFN-γ secretion through neutralization of IL-10 
To address the question whether the increased IL-10 after d 7 of BMDC culture was 
responsible for the reduced T cell proliferation and IFN-γ production, endogenous IL-10 
was neutralized using anti-IL-10 antibody. Titrated numbers of BMDC were cultured 
with or without CpG and then CpG-stimulated cells were incubated with anti-IL-10 
antibody before the addition of allogenic, CFSE-labeled T cells. After d 3, the 
supernatants were collected from BMDC/T cell cocultures and analyzed for IFN-γ 
production. Though, BMDC upon CpG stimulation from both sham and septic mice 
induced T cells derived higher levels of IFN-γ  (Figure 42H), the latter was much lower 
from the septic BMDC/ T cell cocultures as compared to that from sham mice (Figure 
42H). Anti-IL-10 had no effect on non-stimulated cells (Data not shown), but further 
increased the  T cell derived IFN-γ release in response to CpG-stimulated BMDC/T cell 
cocultures from both sham as well as septic mice. However, T cells induced by septic 
BMDC produced significantly more IFN-γ (Figure 43). Therefore, neutralization of 
endogenous IL-10 using anti-IL-10 antibody restored the T cells derived IFN-γ 
production induced by septic BMDC even above levels induced by sham BMDC.  
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Figure 43. Effect of α-IL-10 on IFN-γ production. 
BMC after 24 h CLP or sham operation, were cultured for 7 d to generate BMDC. Titrated numbers of 
BMDC were cultured in the absence and presence of 5 µg/ml CpG in 96-well plates for 18 h and then 
incubated with a dose of 10 µg/ml of anti-IL-10 antibody for an hour before the addition of CFSE-labeled, 
allogenic T cells. After d 3, the supernatants were tested for IFN-γ by ELISA. Data show mean ± SEM of 
triplicate cultures of BMDC with CpG (open squares), and after CpG plus anti-IL-10 incubation (filled 
squares) from sham and septic mice and are representative of two experiments. 
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3.2.6.2 In vivo T cell-stimulatory capacity of BMDC during sepsis  
Furthermore, the capacity of BMDC to induce T cell activation was analyzed in vivo. 
DO11.10 TCR transgenic mice encoding a T cell receptor specific for ovalbumin (OVA) 
peptide (amino acids, 323-339) presented by the MHC class II molecule were used to 
determine in vivo T cell activation. T cells from DO11.10 TCR transgenic mice were 
purified and labeled with CFSE and then injected i.v. into the tail vein of healthy 
BALB/c mice. One day later, these mice were treated with BMDC stimulated with 
ovalbumin alone (Ova) or in combination with CpG (Ova + CpG) from both sham and 
septic mice. After d 3, LNCs were prepared and checked for proliferating T cells by 
gating CFSE-positive CD4+ and D011.10+ viable and proliferating T cells using FACS 
(Figure 44A). In line with the in vitro pattern of proliferation, BMDC from both septic 
and sham mice showed similar in vivo T cell proliferation capacity to Ova (Figure 44B 
and C vs. D) and also to Ova in presence of CpG (Ova + CpG, Figure 44B and E vs. F).  
Further, the isolated LNCs were cultured and restimulated with Ova or ova-peptide for 
three days and the supernatants were assessed for IL-2 and IFN-γ, produced by T cells 
during the proliferation. IL-2, a cytokine for proliferation was found similar in the 
restimulated-LNCs-cultures (restimulation with Ova or ova-peptide) from both the 
groups of mice receiving either Ova (Figure 44G) or Ova + CpG (Figure 44H) BMDC. 
The capacity for IFN-γ production was significantly reduced by these restimulated-LNC-
cultures (Med, Ova and ova-peptide restimulation) from the mice that received Ova + 
CpG-stimulated (Figure 44J) BMDC from the septic mice when compared with 
stimulated-BMDC from the sham mice. IFN-γ secretion from the same restimulated 
LNCs from the mice injected with only ova-stimulated BMDC from both sham and 
septic mice did not show any change (Med. Figure 44I). Therefore, BMDC from septic 
mice had same T cell proliferative capacity but were less potent in inducing T cell 
derived IFN-γ synthesis than BMDC from sham mice. 
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Figure 44. In vivo T cell proliferation and IFN-γ production during sepsis. 
Purified and labeled splenic T cells isolated from D011.10 TCR transgenic mice were injected i.v. into the 
tail vein of a healthy BALB/c mouse. After 24 h, 7 d-BMDC (2 x 106/2 ml/well) were stimulated with 100 
µg/ml ovalbumin (Ova) alone or in the presence of 5 µg/ml CpG (Ova + CpG) for 7 h and 0.5 x 106 
BMDC/30 µl PBS were then injected into the foot pad of BALB/c mice which had received the T cells, 
one day before. Three days later, draining LNCs were prepared and stained for CFSE-positive CD4+ and 
D011.10+ T cells. (A) One of the dot plot showing the CFSE-positive CD4+ and D011.10+ T cells. (B) 
Representative graph out of four independent experiments showing in vivo proliferation of CFSE-positive 
CD4+ and D011.10+ T cells gated in figure 26A from LNCs isolated from the mice injected with sham or 
septic Ova-stimulated and Ova + CpG-stimulated BMDC. (C, D, E and F) Histogram only with the M1 
population of proliferating T cells with or without CpG stimulation from sham or septic BMDC. (G, H, I 
and J) Further, the isolated LNCs were cultured and restimulated in the absence (Med) or presence of 50 
µg/ml Ova and 1 µg/ml ova peptide (Ova-peptide) in triplicates. After 3 d, the supernatants were collected 
and used for IL-2 (G and H) and IFN-γ (I and J) cytokine ELISA. Data show mean ± SD of triplicate co-
cultures of T cells with BMDC from sham (open bars) and septic (black bars) mice each stimulated with 
Ova (G and I) or Ova + CpG stimulation (H and J). Asterisks indicate significant differences between 
cultures of sham and CLP groups. ***, P < 0.0005. 
 
3.2.7 Different myeloid DC Progenitor during polymicrobial sepsis 
The role of myeloid CD4+ DC progenitors was investigated after 24 h of sham or CLP 
operation in order to test whether these progenitors could be associated with the 
enhanced IL-10 release by the dendritic cells. BMC were prepared 24 h post CLP or 
sham operation and stained for CD11c in combination with CD4 and MHC class II 
surface molecules. Total CD11c+ DC were gated and selected for MHCII- surface marker 
to have the DC progenitors. CD4+ expression was studied on these DC progenitors to 
analyze the CD4+ myeloid progenitors (CD11c+MHCII-CD4+; Figure 45A). The 
percentage of the CD4+ DC progenitors was high (Figure 45A and B) from both sham 
(22.38 ± 6.77%) as well as septic mice (9.76 ± 1.94%). However, the percentage of these 
myeloid progenitors after 24 h of sepsis was drastically and significantly reduced up to 
56% (Figure 45A and B). Taken together, the decrease in the percentage of these 
specific progenitors might be responsible for the observed aberration in the cytokine 
response.  
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Figure 45. CD4+ myeloid progenitors during polymicrobial sepsis. 
Twenty-four hours after sham or CLP operation, total BMC were pooled (n=2-3 per group) and stained for 
CD11c+ in combination with CD4+ and MHC class II surface markers. (A) CD11c cells were gated and 
next MHC class II- dendritic cells were selected out of total DC. CD4+ expression was analyzed on these 
CD11c+MHC II- cells (CD4+ myeloid progenitors, Region R1). FACS data shown are representative of 
five independent experiments. (B) The percentage of CD4+ DC progenitors (CD11c+CD4+MHC II-) of 
individual mouse from sham (filled circles) and septic (open circles). Asterisks indicate significant 
differences between cultures of sham and CLP groups. **, P < 0.005. 
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4. Discussion 
 
The present work analyzed the effect of GM-CSF as a potential immunostimulator. 
Several different aspects were investigated. First, we determined the effect of an in vitro 
treatment with GM-CSF in a hemorrhagic shock model. In this context, it could be 
demonstrated that GM-CSF as an immunostimulator could partly reinstate the suppressed 
LPS-induced TNF-α response of peritoneal macrophages following hemorrhagic shock. 
As an additional pathophysiological model we utilized cecal ligation and puncture 
(CLP), a commonly used animal experimental model for severe polymicrobial sepsis [13, 
14, 147, 152, 153]. In this model, we demonstrated that GM-CSF could partly augment 
the extremely suppressed IL-12 production of dendritic cells. However, in this model the 
effect of GM-CSF was not adequate to reach normal levels.  
In order to gather a better understanding of the underlying mechanisms of GM-CSF 
activation of the TNF-α response, we analyzed the interaction between GM-CSF and 
LPS-signaling cascades. The priming effect of GM-CSF in terms of LPS-induced TNF-
α-production was accompanied by a corresponding increase in IκBα phosphorylation and 
the activation of P38MAPK and the phosphorylation of ERK1/2 which could be shown 
for isolated human monocytes, the monocytic cell line THP-1 and murine peritoneal 
macrophages. An involvement of  MAPK activity [154] was suggested and will be 
discussed later. To further understand the possibly involved signaling pathways, the 
analyses were extended to the pathophysiological situation of a hemorrhagic shock. In 
this context, we observed that hemorrhagic shock suppressed IκBα phosphorylation and 
ERK1/2 activation, but enhanced P38 phosphorylation in peritoneal macrophages. In 
vitro treatment with GM-CSF could partly, but not completely restore this alternated 
peritoneal macrophage response also on the basis of the investigated intracellular 
signaling molecules. 
Since GM-CSF therapy has been suggested in clinical trials, especially for neutropenic 
septic patients, which suggest a predominant effect of GM-CSF on the bone marrow, 
further studies dealt with the role of the bone marrow during sepsis. Polymicrobial sepsis 
showed a significant loss of bone marrow cells. The cell loss could not be attributed to 
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the increased apoptosis as the percentage of apoptotic cells was very low. In addition, an 
elevated count of dendritic cells together with monocytes and granulocyte in the blood 
was observed during sepsis suggesting increased release of these cell populations from 
the bone marrow into the blood.  
In spite of a diminished number of BMC during sepsis, septic mice demonstrated a 
higher percentage of total CD11c+ cells. However, similar numbers of MHC II- 
progenitors were found after CLP. During culture, BMC from septic mice proliferated 
strongly and generated up to double the number of cells after d 7 than the corresponding 
cultures of BMC from sham-operated mice. The number of bone marrow derived 
dendritic cells was found akin in both the group of mice after d 7 of culture. In addition, 
BMDC from septic mice, when cultured in the presence of different bacterial stimuli 
produced significantly higher levels of IL-10 but an unchanged amount of TNF-α and 
IL-12. Further, these septic BMDC are less potent in inducing the T cell activation 
observed by the low IFN-γ synthesis by BMDC-induced T cells. Neutralization of 
endogenous IL-10 using anti-IL-10 antibodies could restore the reduced IFN-γ producing 
capacity of Th cells induced by septic BDMC indicating a Th2 promoting IL-10 in this 
sepsis model.  
In order to appraise the possible explanation for the elevated IL-10 cytokine level, 
participation of CD4+ myeloid progenitors was examined. It could be demonstrated that 
twenty-four hours post CLP BMC demonstrated significantly lower number of the 
CD4+MHCII- myeloid progenitor cells. The decreased progenitors could be responsible 
for the enhanced IL-10 level which polarized the Th cells towards Th2 phenotype. 
A reduced cytokine-producing capacity of LPS-stimulated peritoneal macrophages has 
been reported in several experimental settings associated with hemorrhagic shock, which 
are mostly in line with the results of the present study. Sublethal haemorrhage has been 
reported to cause a blunted cytokine response of human circulating monocytes, murine 
peritoneal and splenic macrophages [94]. In alignment with previously reported results 
[94, 155], we also found a reduced LPS-stimulated TNF-α response in peritoneal 
macrophages after hemorrhagic shock. In a similar experimental setting of sublethal 
hemorrhage performed in rats, a depression of LPS-induced TNF-α synthesis of 
peritoneal macrophages has been reported [156]. Also, in sublethal hemorrhage in rats, a 
reduced TNF-α production to subsequent LPS-challenge has been reported for 
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mononuclear cells derived from the intestinal mucosa [20], spleen cells [18, 19] and bone 
marrow cells [19].  
A diminution in LPS-dependent TNF-α synthesis was also observed after cecal ligation 
and puncture (CLP), a model for polymicrobial sepsis. In the presented study, we 
observed a strong reduction in TNF-α producing capacity of splenic macrophages 
collected 24 h after CLP. These data comply with studies performed by various other 
groups. In a recently reported piece of work, a significant suppression of TNF-α in LPS-
stimulated splenic macrophages has been documented in rats receiving a combined insult 
of trauma-hemorrhage and CLP [157]. Also, a significant depression of TNF-α from 
macrophages harvested from either peritoneal cavity or spleen has been suggested during 
late sepsis [158]. In addition, diminished TNF-α production of splenic macrophages has 
been demonstrated numerously after hemorrhagic shock [18, 19, 94].  
Next, the capacity of splenic dendritic cells was examined in terms of IL-12 cytokine 
production. In alignment with a recently reported study [159], we also found a reduced 
CpG-stimulated IL-12 response in splenic dendritic cells during sepsis. We could show 
that DC became unable to secrete bioactive IL-12 in response to CpG, a well known 
inducer of IL-12. A state of impaired IL-12 secretion by splenic DC upon restimulation 
with microbial components has been reported in other models of infectious diseases also 
[160]. The impaired capacity of DC to release IL-12 during sepsis might contribute to the 
inappropriate polarization of Th cells toward Th2 phenotype. Indeed, it has been 
documented that after severe injury or sepsis CD4+ T cell polarization is altered and that 
there develops a later phase of immunosuppression mediated by a predominance of the 
Th2-type cytokines (IL-4 and IL-10;[80] and a depression in the production of IL-2, and 
IFN-γ [80, 161, 162].  
GM-CSF possesses an immunostimulatory capacity and is revealed to boost the 
activation aptitude of monocytes in diverse pathophysiological conditions having 
monocyte dysfunctions [96, 99, 163-166]. The augmenting property of GM-CSF is also 
recognized on mature monocytes and macrophages enhancing their potential to release 
various cytokines such as TNF-α, IL-1β and IL-12 after LPS stimulation, a phenomenon 
commonly referred to as “priming” [87, 88, 99, 165, 167].  
GM-CSF has been suggested as a therapeutic approach for trauma-, shock- or sepsis-
induced immunosuppression [95-97] and when administered in vitro, could restore the 
impaired cytokine response and MHC-class II molecule expression of monocytes from 
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trauma patients [168]. In sepsis-associated immune dysfunction the administration of 
GM-CSF was able to counteract the reduced HLA-DR expression on monocytes as well 
as the reduced TNF-α producing capacity of whole blood cultures [95]. In another 
similar study, blood samples from severely injured patients or patients after major 
surgery show a diminished LPS-induced TNF-α synthesis which can be at least in vitro 
antagonized by GM-CSF [169]. In an uncontrolled clinical trial GM-CSF was given in 
severely injured patients with low granulocyte counts [170]. The study showed that GM-
CSF rapidly elevated granulocyte counts and an increased HLA-DR expression on 
granulocytes was found. Further, no adverse side effects were observed so that the 
treatment approach was considered as safe. In vivo treatment with GM-CSF of mice after 
hemorrhage improved survival and controlled bacterial spreading after secondary septic 
challenge by cecal ligation and puncture [171]. Concerning hemorrhagic shock, GM-CSF 
application in vivo in mice after hemorrhage could counteract the downregulation of 
MHC class II molecules on peritoneal macrophages [172]. In addition, it has been 
demonstrated, that GM-CSF given immediately after reperfusion could restore the 
diminished TNF-α response of spleen and peritoneal cells [94]. A diminished synthesis 
of pro-inflammatory mediators can be induced in vitro by preincubation with endotoxin 
[173]. The status of endotoxin tolerance resembles the situation of the immune response 
observed after hemorrhage. GM-CSF addition to in vitro endotoxin-tolerized human 
monocytes can antagonize this tolerance and restore TNF-α production [164]. 
When GM-CSF is given in vivo, the restoration of the cytokine response may be 
explained by the generation of new macrophages population from the bone marrow, 
which of course is activated by the haematopoietic growth factor GM-CSF. In order to 
rule out a bone marrow dependent effect of GM-CSF, the stimulation with the compound 
in the presented study was performed in vitro. However, also in vitro treatment with GM-
CSF could at least restore the TNF-α response of peritoneal macrophages after shock and 
polymicrobial sepsis. 
Principally, the priming effect of GM-CSF was also evident in dendritic cells after 24 h 
of polymicrobial sepsis. However, the effect of GM-CSF in vitro on CpG-induced IL-12 
production in DC from septic mice was only minimal. GM-CSF could only partially 
counteract the depressed CpG-dependent IL-12 production of dendritic cells from septic 
mice. The stimulatory effect of GM-CSF in DC was not appropriate to reach to the 
normal control level. For the lower responsiveness of GM-CSF towards dendritic cells, 
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one might suggest the downregulation of GM-CSF receptor on dendritic cells but not on 
macrophages during sepsis. We did not study these specific receptors in our experiments. 
It is known that GM-CSF receptor remain unchanged on human monocytes after trauma 
and septic trauma patients [97]. No data is available for dendritic cells and GM-CSF 
receptor expression in sepsis. However, it is known that DC mature during sepsis [80]. 
Kampgen et al has described abundant GM-CSF receptors on mature DC [174]. 
Therefore, a downregulation of the GM-CSF-recpeptor probably does not explain the 
reduced reposne of DC to GM-CSF in sepsis.  
Alternatively, DC during sepsis could become “exhausted” and cannot respond to further 
stimuli e.g. GM-CSF. Indeed, we showed that during sepsis, DC expressed high 
percentage of CD40 and CD86, the surface markers for DC maturation as compared to 
the normal levels indicating that the DC are already matured during sepsis. Although, 
GM-CSF could further enhance the CD86 expression, no change in CD40 was 
recognized after GM-CSF treatment. Therefore, one can speculate that DC could respond 
to GM-CSF in terms of CD86 expression but not CD40, and the overall response is not 
sufficient to compensate the suppressed system during sepsis. 
It is not evident from the present literature on GM-CSF that this cytokine in itself is able 
to activate the NFκB system or induce TNF-α formation in monocytes or macrophage. 
The presented data are in line with the literature since neither TNF-α release nor IκB 
phosphorylation was observed in GM-CSF-stimulated monocytes and macrophages. 
However, GM-CSF preincubation enhanced the LPS-induced TNF-α production without 
inducing this cytokine on its own- a phenomenon commonly referred to as “priming”. 
The underlying mechanism of GM-CSF priming could be sought to be an interaction 
between signaling cascades typical for GM-CSF and LPS. Therefore, we analyzed the 
signaling events activated by GM-CSF and LPS to gain a better perceptive of the basic 
mechanisms involved in the GM-CSF effect. 
We confirmed the priming effect of GM-CSF on LPS-induced TNF-α production in 
normal human circulating monocytes and the human monocytic cell line, THP-1 as well 
as in mouse peritoneal macrophages. The elevated TNF-α response was accompanied by 
a corresponding increase of IκBα and MAPKinase activation [87, 164, 168]. GM-CSF 
enhanced the TNF-α release of LPS-induced human monocytes, THP-1 cells and normal 
mouse peritoneal macrophages. The enhanced TNF-α production in both primed 
monocytes and THP-1 cells could be attributed to the immunostimulatory effect of GM-
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CSF since the increased NFκB binding was accompanied by an increase in cytosolic 
IκBα phosphorylation as shown by electrophoretic mobility shift assay and Western 
blotting of NFκB components in the nuclear extracts.  
GM-CSF also enhanced the ERK1/2 and P38 MAPKinases of LPS-induced human 
monocytes, THP-1 cells and normal mice peritoneal macrophages for the production of 
TNF-α. This effect of GM-CSF for ERK1/2 complies with the study of others where 
they have shown GM-CSF to induce phosphorylation of MEK1/2 and ERK1/2 in isolated 
monocytes [175]. Although, GM-CSF primes the phosphorylation of both ERK1/2 and 
P38 signaling, the priming for LPS-induced TNF-α synthesis seems to be primarily due 
to phosphorylation exerted by ERK1/2 as proved by the inhibitor studies done by our 
own group [154]. PD98059, an inhibitor of ERK1/2 is shown to completely abrogate the 
GM-CSF priming of TNF-α synthesis. In addition, SB203580, that has been used to 
demonstrate the essentiality of P38MAPK for maximum LPS-induced TNF-α synthesis 
[176] did not at all decrease GM-CSF-induced priming for TNF-α synthesis [154]. 
Next, we continued the investigation of these IκBα and MAPK signaling for the 
pathophysiological condition of hemorrhagic shock. Alterations in MAPK (P42/44, P38 
and SAPK/JNK) and NFκB activation and subsequently, a diminished cytokine response 
of murine peritoneal macrophages has been reported following sublethal hemorrhage 
[94].  
As described earlier, we found a reduction in LPS-stimulated TNF-α production in 
peritoneal macrophages after hemorrhagic shock as shown by others as well as our own 
research group [94, 155]. This seems to be accompanied by a lower NFκB activation in 
these cells since we found a lower degree of IκBα phosphorylation. Indeed, NFκB is 
known as one of the predominant transcription factors involved in TNF-α gene activation 
[177, 178]. Suppression of LPS-induced TNF-α synthesis of peritoneal macrophages has 
been reported in an experimental study of sublethal hemorrhage [156], which was also 
accompanied by a diminished activation of the intracellular NFκB signaling pathway 
[179]. The experimental results in animal studies are in line with clinical observation in 
patients with severe injury. Suppression of various cytokines and a long-term-impaired 
expression of NFκB and IκBα have been observed in peripheral blood mononuclear cells 
of major trauma and septic patients [58, 59]. NFkB transcription factor is involved in the 
regulation of immune and acute-phase response at the transcriptional level [180]. NFκB 
regulation may be critical for cytokine gene expression in trauma, because of its presence 
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in the enhancer and promoter regions of proinflammatory cytokine (for example, TNF-α, 
IL-1β, IL-6 and IL-8) genes and its inducibility by several extracellular signals known to 
be present in trauma patients, such as reactive oxygen species, cytokines and endotoxin 
[181, 182]. 
It has also been shown that maximal TNF-α response in macrophages also depends on 
the activation of P38 and P42/44 (ERK1/2) MAPK [155, 183]. Correspondingly, in our 
experimental setting lower TNF-α response was also paralleled by a dampened 
activation of ERK1/2. 
Decreased activation of ERK1/2 as well as Jun-Kinase after LPS stimulation has been 
described in lung and liver tissue 24 h after hemorrhagic shock in rats [57]. On the other 
hand, ERK1/2 activation by hemorrhagic shock on its own has been observed as early as 
1 h after hemorrhage in alveolar macrophages [56] and liver tissue [184]. Therefore, 
ERK1/2 activation seems to be involved in both the early stress response after shock and 
thereafter undergoes a counter regulation with a diminished reactivity. This response 
pattern resembles the production of various cytokines such as TNF-α and IL-6 after 
hemorrhagic shock. 
The other investigated MAPK family member P38MAPK surprisingly shows an opposite 
pattern of activation. In spite of the fact that P38 activation is also necessary for a 
maximal TNF-α production [185-188], the impairment of peritoneal macrophages’ TNF-
α synthesis after haemorrhage was accompanied by an enhanced phosphorylation of P38 
signal. Similar observations have been reported by Angele et al., who found an increased 
LPS-induced P38 phosphorylation in peritoneal macrophages isolated 2 h after 
haemorrhage from male but not female mice [189]. These observations may lead to the 
speculation that P38 activation evokes macrophages’ impaired cytokine response or 
tolerance induction. Indeed, there exists some evidence for this hypothesis. P38MAPK 
seems to be involved in IL-10 secretion, which is in turn a central anti-inflammatory 
mediator dampening TNF-α response also after hemorrhagic shock [190]. Besides the 
possible involvement of P38 in IL-10 regulation, there does not exist any clear 
experimental proof for a shock-induced cytokine response suppression mediated by P38 
activation.  
Summarizing this part of the study, the present work investigated the innate immune 
response after hemorrhagic shock as well as in polymicrobial sepsis. Defects in the 
primary response of macrophages and DC were described on the basis of cytokine 
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response, surface marker expression and intracellular signaling cascade. GM-CSF as a 
potential immunostimulating compound was able to counteract most of these 
deteriorations of the immune response levels. Therefore, this substance may be of 
interest as an immunomodulator in this context. 
In addition to the above described role of GM-CSF as immunomodulator the function of 
GM-CSF as growth factor during polymicrobial sepsis was addressed. During sepsis, a 
large part of DC is lost in lymphoid organs and the remaining DC display an aberrant 
cytokine secretion pattern. Therefore, it is conceivable that there exists a failure of the 
DC generation in the bone marrow that is dependent on GM-CSF. This defect might 
result in an impaired “refill” of the DC pool in lymphoid organs and/or in the release of 
DC with an aberrant cytokine response to bacterial products.  
First, the generation of myeloid cells from the bone marrow during sepsis was analyzed. 
We showed that polymicrobial sepsis induced a strong reduction of total bone marrow 
cells, isolated 24 h post CLP. The percentage of reduction of BMC was found up to 40% 
which is indeed a significant loss of cells to the body’s defense system to combat the 
infection. One might speculate two possibilities for the explanation of this cell loss 
during sepsis. First, there could be enhanced apoptosis and second, there could be an 
increase in the release of different bone marrow cells into the blood during sepsis.  
Apoptosis, the programmed cell death (PCD), plays an important role is the pathology of 
sepsis [191]. A substantial loss of dendritic cells [75], as well as of B and T-helper cells 
due to PCD has been observed in the spleen [192] and thymus [193]. Increased apoptosis 
has also been shown for circulating lymphocytes, particularly CD4 and CD8 T cells, B 
cells and NK cells [194] in case of septic patients. Although, there does exist an ample 
amount of information regarding apoptosis of different cell types in different organs and 
in the circulation, there is paucity of data showing apoptosis of total bone marrow cells 
during sepsis. In the present study, an increased apoptosis of BMC after 24 h of CLP was 
investigated which is in alignment with the studies performed by Chung et al who also 
mentioned an increase in apoptosis in the similar experimental conditions [193]. 
However, the increase in apoptosis could not argue for the reduced number of total BMC 
during sepsis, since, the total percentage of apoptotic cells found during sham as well as 
sepsis was too low to account for this effect. The percentage of both dying and dead cells 
was 6% maximum as confirmed by Annexin V and 7-AAD, respectively.  
Concerning the second parameter of cell loss during sepsis, increased release of bone 
marrow cells into the blood could be another responsible mechanism. Indeed, an 
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enhancement in total leukocyte count was found 24 h after CLP. A significant increase 
for the release of other myeloid cells such as dendritic cells, granulocytes and monocytes 
from the bone marrow into the blood was also observed. There was an increase in the 
release of total CD11c+ cells which showed specially the phenotype of MHC II- DC 
progenitors. It cannot be excluded that the CD11c+ MHCII- population also contain some 
NK cells  although at a lesser extend than DC [195, 196]. Furthermore, analysis of the 
generation of myeloid cells from bone marrow in vitro showed that DC progenitors in the 
bone marrow of septic mice have the same sensitivity to GM-CSF and proliferate in the 
same manner as DC progenitors from sham mice. 
Despite an increased number of DC in the circulation during sepsis, the sepsis-associated 
loss of DC in lymphoid organs cannot be compensated. This suggests that either the 
homing of newly released DC to the lymphoid organs is deregulated or that these cells 
undergo apoptosis after reaching these organs. However, it can not be told for sure about 
the deregulation of homing to different organs since no experiments were performed to 
track the migration of the cells from bone marrow to different organs such as spleen. 
Thus, the failure of the immune system to replace the sepsis-associated loss of DC in the 
lymphoid organs seems not to be mediated by an impaired generation and release of DC 
into the circulation. 
Not only the depletion of dendritic cells was found during sepsis but also the remaining 
DC showed a deviated cytokine production at least in the spleen [80]. This altered 
cytokine production might be the consequence of a sepsis-mediated modulation of 
splenic DC or it might represent the phenotype of DC after homing into the spleen. The 
possibility of a “new” DC population was supported by the finding that DC generated 
from bone marrow of septic mice in vitro display an altered cytokine secretion pattern in 
comparison to BMDC from sham mice. TNF-α, IL-10, IL-12 were selected to study the 
cytokines behavior of BMDC during sepsis. Among the pro-inflammatory cytokines, 
TNF-α was selected since it is recognized as a key cytokine mediating the pro-
inflammatory response [197-201]. Next, we studied IL-12, a heterodimeric cytokine 
consisting of p35 and p40 subunits [1, 202]. It is known that IL-12 is produced by 
phagocytes, B lymphocytes and dendritic cells in response to bacteria or bacterial 
products [203-205]. In addition, IL-12 is required for the production of IFN-γ by T 
lymphocytes and supports the development of the Th1 phenotype of CD4+ T cells [162]. 
Concerning IL-10, during the last decade, several studies indicate that among the anti-
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inflammatory cytokines, it plays an important role in sepsis response [36, 206] and the 
expression of IL-10 may contribute to sepsis-induced immunosuppression [36, 80]. In the 
present work, we showed that the secretion of TNF-α from both sham and septic mice 
was found to be similar. We observed that 24 h after CLP, DC were unable to secrete 
bioactive IL-12 in the absence of any stimulation. Cytokine synthesis of untreated 
BMDC might represent the activity of BMDC in situ. However, BMDC from both sham 
as well as septic mice could secrete IL-12 in response to LPS + CD40L or CpG, both 
well known inducers of IL-12 and also in the presence of other stimuli such as PGN or 
bacteria. Although, BMDC could secrete IL-12 in response to different stimuli, we found 
no change among both the groups of mice. Instead, BMDC from septic mice secreted 
prominent levels of IL-10 ex vivo, which were further enhanced upon stimulation with 
otherwise IL-12-inducing agents. The reason for this abnormal cytokines secretion 
remains unclear. IL-12, the counter-regulatory cytokine for IL-10 seems not to be 
responsible for this enhanced IL-10 as no change was observed during sepsis concerning 
IL-12. In addition to test the functional characteristic of BMDC, the DC were also 
investigated for their phenotypic expression of surface co-stimulatory molecules such as 
CD40 and CD86, the maturation markers of dendritic cells. BMDC did not enhance the 
expression of CD40 or CD86 upon sepsis within 24. Thus, In spite of no change in terms 
of BMDC surface marker expression, sepsis modulated the bone marrow derived 
dendritic cells in terms of cytokine secretion. BMDC mirror in part phenotype of splenic 
DC during sepsis. This supports the hypothesis of “new” population in the spleen. 
Further, the question whether altered DC behavior could be relevant for T cell 
polarization, was addressed. The capacity of BMDC to induce T cell activation was 
evaluated both in vitro and in vivo. In vitro T cell proliferative capacity of BMDC was 
found unchanged after 24 h of CLP operation. BMDC from septic mice induced a similar 
proliferation of T cells as did BMDC from sham mice. However, in spite of having the 
same proliferation potential, T cells stimulated with BMDC from septic mice released 
less IFN-γ than T cells stimulated with BMDC from sham mice. The results form in vitro 
studies complied with the in vivo BMDC-induced T cell activation studies. The 
predominance of IL-10 released from BMDC during sepsis as shown here might polarize 
Th cells towards Th2 and in parallel might inhibit the development of a Th1 response 
that is required for the effective clearance of bacterial infections [207]. The finding that 
BMDC from septic mice secreted elevated levels of Th2 cytokines upon different 
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stimulation with bacterial components further supported this conjecture. The suppressive 
activity of IL-10 on Th1 cell polarization and proliferation might explain the finding that 
DC from septic mice were inferior to DC from controls in T cell activation. Taking the 
fact of IL-10 into consideration, endogenous IL-10 was neutralized using anti-IL-10 
antibody which interestingly restored the decreased IFN-γ production induced by BMDC 
from septic mice. This further added the proof that IL-10 might be responsible for 
skewing the system towards Th2 type of phenotype and on other hand inhibiting the Th1 
system. 
The mechanisms underlying the reduced capacity of BMDC from septic mice to polarize 
T cells towards Th1 remain unclear. Th1 cell proliferation is impaired by the activity of 
Th2 cells or by regulatory T cells. BMDC-induced T cells were not tested for the release 
of Th2 cytokines like IL-13, IL-10 or IL-5. On the other hand, BMDC were shown to 
induce the expansion of naturally occurring CD4+CD25+ regulatory T cells which 
suppressed the activation of DC mediated activation of CD4+CD25- T cells [208]. These 
Treg cells inhibit the proliferation and cytokine release of antigen-specific Th1 cells. 
Therefore, it might be possible that BMDC expand and activate Treg cells that prevent 
the induction of a protective Th1 immune response. Further characterization of BMDC-
activated T cells is needed to clarify the mechanisms of impaired Th1-polarization. 
DC progenitors in the bone marrow from septic mice underwent several rounds of 
proliferation during the seven-day-lasting culture. The finding that during this long-
lasting 7 d culture BMDC from septic mice differentiate to an altered phenotype than DC 
progenitor from sham mice is remarkable. This altered differentiation might originate 
from an altered composition of the environment or from a changed subtype composition 
of DC progenitors. It is shown that the presence of IL-10 or high amounts of LPS during 
the culture and BMC development generate DC characterized by enhanced IL-10 which 
favors Th2 polarization. However, in this study, no IL-10 was detected in the 
supernatants from untreated bone marrow cells from septic mice representing the 
cytokines milieu in situ. Also, no LPS was observed in the bone marrow cell cultures. 
This suggests that neither LPS nor IL-10 because of their absence during the culture of 
bone marrow cells can explain the increased Th2 polarization during sepsis.  
The other possibility of different subtype composition might explain the enhanced IL-10 
and induction of Th cells towards Th2 phenotype. Therefore, we looked for different 
subsets as the explanation for the enhanced IL-10 level and developed Th2 pattern. DC 
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are known to be heterogeneous which can be distinguished by a variety of cell surface 
markers and functional attributes [209]. It is of great interest to know whether differential 
immune responses are mediated by distinct subsets or simply reflect a functional stage of 
all DC. There is therefore great development in delineating more precisely the 
developmental pathways between immediate DC precursors and their progeny. 
CD11c+MHC II- precursor DC population in mouse bone marrow like CD11c+MHC II- 
blood cells has been identified to possess the capacity to generate various mature DC 
populations in vivo. CD11c+MHC II- precursor DC in bone marrow was shown to have 
two different  B220+ and B220- subpopulations, which are morphologically, 
immunophenotypically, and functionally distinct [210].  
However, the presence of GM-CSF expands the bone marrow progenitors to develop 
preferentially into myeloid DC [62, 63]. So far there is not present enough literature for 
myeloid progenitors. Myeloid DC are characterized by CD11c+MHAC+ surface markers 
that also originate from CD11c+MHC II- DC progenitors. We investigated the CD4+ DC 
progenitors (CD4+CD11c+MHC II-) in the bone marrow cells after 24 h of CLP 
operation. Interestingly, we found a strong reduction in the percentage of these 
progenitors in septic BMC as compared to sham BMC. It might be speculated that this 
progenitor population might be the responsible factor for the enhanced IL-10 release by 
BMDC during sepsis and for the polarization towards Th2 like phenotype. Although, it 
was not proved in the present study but it can be investigated by deleting the CD4+ 
progenitor population out of bone marrow cells and then looking for the effect upon their 
depletion for IL-10 release by dendritic cells.  
Taken together, GM-CSF mediates the generation of bone marrow-derived DC that 
display a Th2-promoting phenotype in case of bone marrow cells from septic mice. 
Generation of such Th2-polarizing DC during sepsis in vivo might explain the altered 
phenotype of DC in lymphoid organs during sepsis. 
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5. Summary 
 
After hemorrhagic shock and during sepsis, antigen-presenting cells loose the capacity to 
respond to bacteria or bacterial products with the secretion of pro-inflammatory 
cytokines. This malfunction of antigen-presenting cells like macrophages and dendritic 
cells is associated with the development of immunosuppression and might lead to multi-
organ failure and death. GM-CSF is a cytokine that is known to modulate the cytokine 
secretion of antigen-presenting cells and additionally acts as growth factor on myeloid 
cells. In the present study, the capacity of GM-CSF to restore the secretion of pro-
inflammatory cytokines by macrophages and dendritic cells was investigated in animal 
models for hemorrhagic shock and polymicrobial sepsis. Additionally, it was tested in 
vitro, whether GM-CSF might mediate the differentiation of competent dendritic cells 
from bone marrow during sepsis.  
GM-CSF restored the suppressed LPS-induced TNF-α release from the splenic 
macrophages after hemorrhagic shock and during sepsis up to levels observed for the 
respective LPS-stimulated cells from sham mice. GM-CSF partially but not completely 
restored the suppressed LPS-induced TNF-α production from the peritoneal 
macrophages after hemorrhagic shock. The GM-CSF-mediated restoration of the LPS-
induced TNF-α secretion by peritoneal macrophages was verified on the level of IκBα 
phosphorylation. In addition GM-CSF effects were also associated with increased levels 
of the activated forms of the signaling molecules P38MAPK and ERK1/2, possibly 
suggesting an involvement of one of these MAPK in the stimulatory effects of GM-CSF. 
In contrast, GM-CSF was inefficient in restoring the LPS-induced cytokine response by 
dendritic cells from septic animals. Analyses of the phenotype of dendritic cells that 
differentiated from bone marrow progenitors of septic mice in the presence of GM-CSF 
showed that these dendritic cells display an aberrant cytokine response and fail to 
polarize Th lymphocytes towards Th1. This malfunction of in vitro generated dendritic 
cells from septic mice is associated with an increased secretion of IL-10 in response to 
immunostimulatory bacterial oligonucleotides and resembles the deviated cytokine 
response from splenic dendritic cells during sepsis. The absence of IL-10 or LPS during 
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the GM-CSF-dependent differentiation of dendritic cells suggests that another 
mechanism was responsible for the development of the abnormal phenotype from BMDC 
from septic mice. A reduced population of CD4+ dendritic cell progenitors with so far 
unknown function was found in the bone marrow of septic mice and might play a role in 
the aberrant differentiation of dendritic cells during sepsis. In summary, GM-CSF 
therapy might reinforce the macrophages’ antibacterial defence mechanisms during 
hemorrhagic shock and sepsis-associated immunosuppression. However, differentiation 
of dendritic cells from bone marrow during sepsis might result in an aberrant phenotype 
of dendritic cells that prevent the development of a protective Th1 response and, thereby, 
further aggravates immunosuppression.  
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